


A COMPILATION OF GENES IN EACH CHROMOSOME

CANCER



GENES

SATISH RAMALINGAM
EDITOR

Bentham Books

Cancer Genes

(Volume 1)

Edited by

Satish Ramalingam

*Department of Genetic Engineering, School of
Bioengineering*

SRM Institute of Science and Technology

Kattankulathur-603203

India

Cancer Genes (Volume 1)

Editor: Satish Ramalingam

ISBN (Online): 978-981-5080-29-2

ISBN (Print): 978-981-5080-30-8

ISBN (Paperback): 978-981-5080-31-5

© 2023, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

First published in 2023.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

FOREWORD	i
PREFACE	ii
LIST OF CONTRIBUTORS	iii
CHAPTER 1 CHROMOSOME 1	1
<i>Ravi Gor, Saurav Panicker and Satish Ramalingam</i>	
1. INTRODUCTION	1
1.1. MUC1: Mucin-1 Chromosome 1; 1q22	2
1.2. NTRK1: Neurotrophic receptor Tyrosine Kinase-1 Location: Chromosome 1; 1q23.3	2
1.3. PBX1: Pre-B-Cell Leukemia Transcription Factor-1 Chromosome 1; 1q23.3	3
1.4. ABL2: Tyrosine Protein Kinase ABL2 Chromosome 1; 1q25.2	3
1.5. Notch2: Neurogenic Locus Notch Homolog Protein-2 Chromosome 1; 1p12	4
1.6. NRAS: NRAS Proto-Oncogene Chromosome 1; 1p13.2	5
1.7. JUN: Jun Proto-Oncogene Chromosome 1; 1p32.1	5
1.8. TAL1: T-Cell Acute Lymphocytic Leukemia Protein-1 Chromosome 1; 1p33	6
1.9. JAK1: Janus Kinase-1 Chromosome 1; 1p31.3	6
1.10. SFPQ: Splicing Factor, Proline and Glutamine-Rich Chromosome 1; 1p34.3	7
1.11. ARNT: Aryl Hydrocarbon Translocator Chromosome 1; 1q21.3	7
1.12. REG4: Regenerating Islet-Derived Protein-4 Chromosome 1; 1p12	8
1.13. CD58: Cluster of Differentiation 58 Chromosome 1; 1p13.1	8
1.14. RAP1A: Ras-Related Protein Rap-1A Chromosome 1; 1p13.2	8
1.15. GSTM3: Glutathione S-Transferase M3C Chromosome 1; 1p13.3	9
1.16. YBX1: Y-Box Binding Protein Chromosome 1; 1p34.2	9
1.17. STMN1: Stathmin-1 Chromosome 1; 1p36.11	9
1.18. WNT4: WNT Family Member 4 Chromosome 1; 1p36.12	10
1.19. E2F2: Transcription Factor E2F2 Chromosome 1; 1p36.12	10
1.20. PARK7: Parkinson Disease Protein-7 Chromosome 1; 1p36.23	10
1.21. ARID1A: AT-Rich Interaction Domain-1A Chromosome 1; 1p36.11	11
1.22. ENO1: Enolase-1 Chromosome 1; 1p36.23	11
1.23. SMYD3: SET and MYND Domain-Containing Protein-3 Chromosome 1; 1q44	12
1.24. TP53BP2: Tumor Suppressor p53 Binding Protein-2 Chromosome 1; 1q41	12
1.25. PDPN: Podoplanin Chromosome 1; 1p36.21	12
1.26. SHC1: SHC Adaptor Protein-1 Chromosome 1; 1q21.3	13
1.27. MDM4: Mouse Double Minute-4 Chromosome 1; 1q32.1	13
1.28. ADAR: Adenosine Deaminases Acting on RNA Chromosome 1; 1q21.3	13
1.29. HDGF: Hepatoma-Derived Growth Factor Chromosome 1; 1q23.1	14
1.30. MUTYH: mutY DNA Glycosylase Chromosome 1; 1p34.1	14
1.31. SDHB: Succinate Dehydrogenase Iron-Sulfur Subunit B Chromosome 1; 1p36.13	14
1.32. EXO1: Exonuclease-1 Chromosome 1; 1q43	14
1.33. FH: Fumarate Hydratase Chromosome 1; 1q43	15
1.34. RHOC: RAS Homolog Gene Family Member C Chromosome 1; 1p13.2	15
1.35. TGFBR3: Transforming Growth Factor-Beta Receptor-3 Chromosome 1; 1p22.1	15
1.36. CCN1: CCN Family Member-1 Chromosome 1; 1p22.3	16
1.37. IL23R: Interleukin 23 Receptor Chromosome 1; 1p31.3	16
1.38. ROR1: Receptor Tyrosine kinase-Like Orphan Receptor-1 Chromosome 1; 1p31.3	16
1.39. PTPRF: Protein Tyrosine Phosphatase Receptor Type-F Chromosome 1; 1p34.2	17
1.40. PUM1: Pumilio-1 Chromosome 1; 1q35.2	17
CONCLUSION	17
REFERENCES	18

CHAPTER 2 CHROMOSOME 2	28
<i>Thilaga Thirugnanam, Saurav Panicker and Satish Ramalingam</i>	
1.1. APOB - APOLIPOPROTEIN B CHROMOSOME 2; 2p24.1	28
1.2. BOLL - BOULE HOMOLOG, RNA BINDING PROTEIN CHROMOSOME 2; 2q33.1	29
1.3. BUB1 - BUB1 MITOTIC CHECKPOINT SERINE/THREONINE KINASE CHROMOSOME 2; 2q13	29
1.4. CCL20 - C-C MOTIF CHEMOKINE LIGAND 20 CHROMOSOME 2; 2q36.3	29
1.5. CFLAR - CASP8 AND FADD-LIKE APOPTOSIS REGULATOR CHROMOSOME 2; 2q33.1	30
1.6. CREB1 - CAMP RESPONSIVE ELEMENT BINDING PROTEIN 1 CHROMOSOME 2; 2q33.3	30
1.7. CTLA4 - CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 CHROMOSOME 2; 2q33.2	30
1.8. CXCR4 - C-X-C MOTIF CHEMOKINE RECEPTOR 4 CHROMOSOME 2; 2q22.1	31
1.9. CYP1B1 - CYTOCHROME P450 FAMILY 1 SUBFAMILY B MEMBER 1 CHROMOSOME 2; 2p22.2	32
1.10. DDX1 - DEAD-BOX HELICASE 1 CHROMOSOME 2; 2p24.3	32
1.11. DNMT3A - DNA METHYL TRANSFERASE 3 ALPHA CHROMOSOME 2; 2p23.3	32
1.12. EFEMP1 - EGF CONTAINING FIBULIN EXTRACELLULAR MATRIX PROTEIN 1 CHROMOSOME 2; 2p16.1	33
1.13. EPCAM - EPITHELIAL CELL ADHESION MOLECULE CHROMOSOME 2; 2p21	33
1.14. ERBB4 - ERB-B2 RECEPTOR TYROSINE KINASE 4 CHROMOSOME 2; 2q34	33
1.15. FHL2 - FOUR AND A HALF LIM DOMAINS 2 CHROMOSOME 2; 2q12.2	34
1.16. FOSL2 - FOS LIKE 2, AP-1 TRANSCRIPTION FACTOR SUBUNIT CHROMOSOME 2; 2p23.2	34
1.17. FRZB - FRIZZLED RELATED PROTEIN CHROMOSOME 2; 2q32.1	34
1.18. FZD7 - FRIZZLED CLASS RECEPTOR 7 CHROMOSOME 2; 2q33.1	35
1.19. GREB1 - GROWTH REGULATING ESTROGEN RECEPTOR BINDING 1 CHROMOSOME 2; 2p25.1	35
1.20. GLI2 - GLI FAMILY ZINC FINGER 2 CHROMOSOME 2; 2q14.2	35
1.21. HDAC4 - HISTONE DEACETYLASE 4 CHROMOSOME 2; 2q37.3	36
1.22. HOXD10 - HOMEODOMAIN D10 CHROMOSOME 2; 2q31.1	36
1.23. ID2 - INHIBITOR OF DNA BINDING 2 CHROMOSOME 2; 2p25.1	36
1.24. IDH1 - ISOCITRATE DEHYDROGENASE (NADP (+)) 1 CHROMOSOME 2; 2q34	37
1.25. IL1B - INTERLEUKIN 1 BETA CHROMOSOME 2; 2q14.1	37
1.26. ING5 - INHIBITOR OF GROWTH FAMILY MEMBER 5 CHROMOSOME 2; 2q37.3	37
1.27. IRS1- INSULIN RECEPTOR SUBSTRATE 1 CHROMOSOME 2; 2q36.3	38
1.28. MEIS1 - MEIS HOMEODOMAIN 1 CHROMOSOME 2; 2p14	38
1.29. MYCN - MYCN PROTO-ONCOGENE, BHLH TRANSCRIPTION FACTOR CHROMOSOME 2; 2p24.3	38
1.30. NCOA1 - NUCLEAR RECEPTOR COACTIVATOR 1 CHROMOSOME 2; 2p23.3	39
1.31. NR4A2 - NUCLEAR RECEPTOR SUBFAMILY 4 GROUP A MEMBER 2 CHROMOSOME 2; 2q24.1	39
1.32. ODC1 - ORNITHINE DECARBOXYLASE 1 CHROMOSOME 2; 2p25.1	39
1.33. PAX3 - PAIRED BOX 3 CHROMOSOME 2; 2q36.1	40
1.34. PAX8 - PAIRED BOX 8 CHROMOSOME 2; 2q14.1	40
1.35. RALB - RAS LIKE PROTO-ONCOGENE B CHROMOSOME 2; 2q14.2	40
1.36. RANBP2 - RAN BINDING PROTEIN 2 CHROMOSOME 2; 2q13	41

1.37. REG1A - REGENERATING FAMILY MEMBER 1 ALPHA CHROMOSOME 2;	
2p12	41
1.38. REL - REL PROTO-ONCOGENE, NF-KB SUBUNIT CHROMOSOME 2; 2p16.1	41
1.39. REV1 - REV1 DNA DIRECTED POLYMERASE CHROMOSOME 2; 2q11.2	42
1.40. RHOB - RAS HOMOLOG FAMILY MEMBER B CHROMOSOME 2; 2p24.1	42
1.41. ROCK2 – RHO-ASSOCIATED COILED-COIL CONTAINING PROTEIN KINASE 2	
CHROMOSOME 2; 2p25.1	42
1.42. RRM2 - RIBONUCLEOTIDE REDUCTASE REGULATORY SUBUNIT M2	
CHROMOSOME 2; 2p25.1	43
1.43. SDC1 – SYNDECAN 1 CHROMOSOME 2; 2p24.1	43
1.44. SOX11 – SRY-BOX TRANSCRIPTION FACTOR 11 CHROMOSOME 2; 2p25.2	43
1.45. STAT1 - SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1	
CHROMOSOME 2; 2q32.2	44
1.46. SUMO1 - SMALL UBIQUITIN-LIKE MODIFIER 1 CHROMOSOME 2; 2q33.1	44
1.47. TCF7L1 - TRANSCRIPTION FACTOR 7 LIKE 1 CHROMOSOME 2; 2p11.2	45
1.48. TIA1 - TIA1 CYTOTOXIC GRANULE ASSOCIATED RNA BINDING PROTEIN	
CHROMOSOME 2; 2p13.3	45
1.49. TRPM8 - TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL	
SUBFAMILY M, MEMBER 8 CHROMOSOME 2; 2q37.1	45
1.50. TWIST2 - TWIST FAMILY BHLH TRANSCRIPTION FACTOR 2 CHROMOSOME	
2; 2q37.3	46
CONCLUSION	46
REFERENCES	46
CHAPTER 3 CHROMOSOME 3	52
<i>Saurav Panicker and Satish Ramalingam</i>	
1. INTRODUCTION	52
1.1. BCL6: B-Cell Lymphoma 6 Chromosome 3; 3q27.3	52
1.2. RAF1: Rapidly Accelerated Fibrosarcoma, Chromosome 3; 3p25.2	53
1.3. TFG: Tropomyosin-Receptor Kinase Fused Gene Chromosome 3; 3q12.2	53
1.4. SRGAP3: SLIT-ROBO Rho GTPase-Activating Protein 3 Chromosome 3; 3p25.3	53
1.5. GATA2: GATA Binding Protein 2 Chromosome 3; 3q21.3	53
1.6. RPN1: Ribophorin I Chromosome 3; 3q21.3	55
1.7. CNBP: Cellular Nucleic Acid-Binding Protein Chromosome 3; 3q21.3	55
1.8. FHIT: Fragile Histidine Triad Diadenosine Triphosphatase Chromosome 3; 3p14.2	55
1.9. PPARG: Peroxisome Proliferator-Activated Receptor Gamma Chromosome 3; 3p25.2	55
1.10. MECOM: MDS1 and EVI1 Complex Locus Chromosome 3; 3q26.2	55
1.11. MITF – Melanocyte Inducing Transcription Factor Chromosome 3; 3p13	56
1.12. FOXP1: Forkhead Box Protein P1 Chromosome 3; 3p13	56
1.13. PBRM1: Polybromo-1 Chromosome 3; 3p21.1	56
1.14. BAP1: BRCA1 Associated Protein 1 Chromosome 3; 3p21.1	57
1.15. NCKIPSD: NCK Interacting Protein with SH3 Domain Chromosome 3; 3p21.31	57
1.16. SETD2: Set Domain Containing 2 Chromosome 3; 3p21.31	57
1.17. CTNNB1 Gene: Catenin Beta 1 Chromosome 3; 3p22.1	57
1.18. MYD88: Myeloid Differentiation Primary Response 88 Chromosome 3; 3p22.2	58
1.19. CBLB: Cbl Proto-Oncogene B Chromosome 3; 3q13.11	58
1.20. FOXL2: Forkhead Box Protein L2 Chromosome 3; 3q22.3	58
1.21. WWTR1: WW Domain Containing Transcription Regulator 1 Chromosome 3; 3q25.1	58
1.22. GMPS: Guanine Monophosphate Synthase Chromosome 3; 3q25.31	59
1.23. MLF1: Myeloid Leukemia Factor 1 Chromosome 3; 3q25.32	59

1.24. PIK3CA: Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Chromosome 3; 3q26.32	59
1.25. SOX2: Sex-Determining Region Y [SRY]-Box Rranscription Factor 2 Chromosome 3; 3q26.33	59
1.26. ETV5: ETS Variant Transcription Factor 5 Chromosome 3; 3q27.2	60
1.27. EIF4A2: Eukaryotic Translation Initiation Factor 4A, Isoform 2 Chromosome 3; 3q27.3	60
1.28. LPP: Lipoma Preferred Partner Chromosome 3; 3q27.3-q28	60
1.29. RASSF1: Ras Association Domain-Containing Protein 1 Chromosome 3; 3p21.31	60
1.30. MLH1: MutL Homolog 1 Chromosome 3; 3p22.2	61
1.31. VHL: Von Hippel-Lindau Chromosome 3; 3p25.3	61
1.32. XPC: Xeroderma Pigmentosum Complementation Group C [XP Complex Subunit C] Chromosome 3; 3p25.1	61
1.33. FANCD2: Fanconi Anemia Complementation Group D2 Protein Chromosome 3; 3p25.3	61
1.34. POU1F1: POU Class 1 Homeobox 1 Chromosome 3; 3p11.2	62
1.35. EPHA3: EPH Receptor A3 Chromosome 3; 3p11.1	62
1.36. ROBO1: Roundabout Guidance Receptor 1 Chromosome 3; 3p12.3	62
1.37. LRIG1: Leucine-Rich Repeats and Immunoglobulin-Like Domains 1 Chromosome 3; 3p14.1	62
1.38. ADAMTS9: ADAM Metallopeptidase with Thrombospondin Type 1 Motif 9 Chromosome 3; 3p14.1	63
1.39. WNT5A: Wnt Family Member 5A. Chromosome 3; 3p14.3	63
1.40. CCR1: C-C Motif Chemokine Receptor 1 Chromosome 3; 3p21.31	63
CONCLUSION	63
REFERENCES	64

CHAPTER 4 CHROMOSOME 4 71

Anindita Menon, Ravi Gor, Saurav Panicker and Satish Ramalingam

1.1. AAA2 - AORTIC ANEURYSM, FAMILIAL ABDOMINAL 2 CHROMOSOME 4; 4q31	71
1.2. ABCG2- ATP BINDING CASSETTE SUBFAMILY G MEMBER DOMAIN 29 CHROMOSOME 4; 4q34.1	72
1.3. AFF1- AF4/FMR2 FAMILY MEMBER 1 CHROMOSOME 4; 4q21.3-q22.1	72
1.4. AFP-ALPHA-FETOPROTEIN CHROMOSOME 4; 4q13.3	72
1.5. AREG- AMPHIREGULIN CHROMOSOME 4; 4q13.3	74
1.6. CCNG2- CYCLIN G2 CHROMOSOME 4; 4q21.1	74
1.7. CD38 CHROMOSOME 4; 4p15.32	74
1.8. CLOCK- CLOCK CIRCADIAN REGULATOR CHROMOSOME 4; 4q12	74
1.9. CXCL1- C-X-C MOTIF CHEMOKINE LIGAND 1 CHROMOSOME 4; 4q13.3	75
1.10. CXCL 2- C-X-C MOTIF CHEMOKINE LIGAND 2 CHROMOSOME 4; 4q13.3	75
1.11. CXCL3- C-X-C MOTIF CHEMOKINE LIGAND 3 CHROMOSOME 4; 4q13.3	75
1.12. CXCL5- C-X-C MOTIF CHEMOKINE LIGAND 5 CHROMOSOME 4; 4q13.3	76
1.13. CXCL9- C-X-C MOTIF CHEMOKINE LIGAND 9 CHROMOSOME 4; 4q21.1	76
1.14. CXCL11- C-X-C MOTIF CHEMOKINE LIGAND 11 CHROMOSOME 4; 4q21.1	76
1.15. CXCL13- C-X-C MOTIF CHEMOKINE LIGAND 13 CHROMOSOME 4; 4q21.1	77
1.16. CTBP1- C-TERMINAL BINDING PROTEIN 1 CHROMOSOME 4; 4p16.3	77
1.17. DUX4L1- DOUBLE HOMEBOX 4 LIKE 1 CHROMOSOME 4; 4q35.2	78
1.18. EPHA5- ERYTHROPOIETIN PRODUCING HEPATOCELLULAR RECEPTOR A5 CHROMOSOME 4; 4q13.1- q13.2	78
1.19. EREG- EPIREGULIN CHROMOSOME 4; 4q13.3	78

1.20. FBXW7- F-BOX WD REPEAT DOMAIN CONTAINING 7 CHROMOSOME 4; 4q31.3	78
1.21. GNRHR- GONADOTROPIN-RELEASING HORMONE RECEPTOR CHROMOSOME 4; 4q13.2	79
1.22. IGFBP7- INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 7 CHROMOSOME 4; 4q12	79
1.23. IL2- INTERLEUKIN 2 CHROMOSOME 4; 4q27	80
1.24. KIT- KIT PROTO-ONCOGENE RECEPTOR TYROSINE KINASE CHROMOSOME 4; 4q12	80
1.25. MUC7- MUCIN 7 CHROMOSOME 4; 4q13.3	80
1.26. PCDH7- PROTOCADHERIN 7 CHROMOSOME 4; 4p15.1	80
1.27. PDGFRA- PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA CHROMOSOME 4;4q12	81
1.28. PPARGC1A- PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1 ALPHA CHROMOSOME 4; 4p15.2	81
1.29. RASSF6- RAS ASSOCIATION DOMAIN FAMILY MEMBER 6 CHROMOSOME 4; 4q13.3	82
1.30. RBPJ- RECOMBINANT SIGNAL BINDING PROTEIN FOR IMMUNOGLOBIN KAPPA J REGION CHROMOSOME 4; 4p15.2	82
1.31. RFC1- REPLICATION FACTOR C SUBUNIT 1 CHROMOSOME 4; 4p14	82
1.32. S100P- S100 CALCIUMBINDING PROTEIN P CHROMOSOME 4; 4p16.1	82
1.33. SLC34A2- SOLUTE CARRIER FAMILY 34 MEMBER 2 CHROMOSOME 4; 4p15.2	83
1.34. SLIT2- SLIT GUIDANCE LIGAND 2 CHROMOSOME 4; 4p15.31	83
1.35. SPP1 SECRETED PHOSPHOPROTEIN 1 CHROMOSOME: 4; 4q22.1	83
1.36. SPRY1 SPROUTY RTK SIGNALLING ANTAGONIST 1 CHROMOSOME: 4; 4q28.1	84
1.37. TACC3-TRANSFORMING ACIDIC COILED COIL PROTEIN 3 CHROMOSOME: 4;4p16.3	84
1.38. TLR1- TOLL-LIKE RECEPTOR 1 CHROMOSOME 4; 4p14	84
1.39. TET2-TET METHYLCYTOSINE DIOXYGENASE2 CHROMOSOME 4; 4q24	84
1.40. UCHL1- UBIQUITIN C- TERMINAL HYDROLASE L1 CHROMOSOME 4; 4p13	85
CONCLUSION	85
REFERENCES	85
CHAPTER 5 CHROMOSOME 5	90
<i>Sayooj Madhusoodanan, Saurav Panicker and Satish Ramalingam</i>	
1.1. AACSP1: ACETOACETYL-COA SYNTHETASE PSUEDOGENE 1. CHROMOSOME 5; 5q35.3	90
1.2. ABLIM3: ACTIN BINDING LIM PROTEIN FAMILY MEMBER 3. CHROMOSOME 5; 5q32	91
1.3. ACOT12: ACYL-COA THIOESTERASE 12. CHROMOSOME 5; 5q14.1	91
1.4. ACSL6: ACYL-COA SYNTHETASE LONG-CHAIN FAMILY 6. CHROMOSOME 5; 5q31.1	91
1.5. ACTBL2: ACTIN BETA LIKE 2 [HOMO AAPIENS (HUMAN)]. CHROMOSOME 5; 5q11.2	92
1.6. ACTBP2: ACTB PSEUDOGENE 2 [HOMO SAPIENS (HUMAN)]. CHROMOSOME 5; 5q14.1	92
1.7. ADAM19: ADAM METALLOPEPTIDASE DOMAIN 19. CHROMOSOME 5; 5q33.3	93
1.8. ADAMTS12: ADAM METALLOPEPTIDASE WITH THROMBOSPONDIN TYPE 1 MOTIF 1. CHROMOSOME 5; 5P13.3-p13.2	93

1.9. ADAMTS16: ADAM METALLOPEPTIDASE WITH THROMBOSPONDIN TYPE 1 MOTIF 16. CHROMOSOME 5; 5p15.32	93
1.10. ADRA1B: ADRENO RECEPTOR ALPHA 1B MOTIF 16. CHROMOSOME 5; 5q33.3	94
1.11. ADRB2: ADRENOCEPTOR BETA 2. CHROMOSOME 5; 5q33.3	94
1.12. AFAP1L1: ACTIN FILAMENT-ASSOCIATED PROTEIN 1. CHROMOSOME 5; 5q32	95
1.13. AFF4: AF4/FMR2 FAMILY MEMBER 4. CHROMOSOME 5; 5q31.1	96
1.14. AGGF1: ANGIOGENIC FACTOR WITH G-PATCH AND FHA DOMAINS 1. CHROMOSOME 5; 5q13.3	96
1.15. AHHR: ARYL-HYDROCARBON RECEPTOR REPRESSOR. CHROMOSOME 5; 5p15.33	97
1.16. AMACR: ALPHA-METHYLACYL-COA RACEMASE. CHROMOSOME 5; 5P13.2	98
1.17. ANKHD1: ANKYRIN REPEAT AND KH DOMAIN CONTAINING 1. CHROMOSOME 5; 5q31.3	98
1.18. ANXA2R: ANNEXIN A2 RECEPTOR. CHROMOSOME 5; 5p12	98
1.19. APC: APC REGULATOR OF WNT SIGNALING PATHWAY/ADENOMATOUS POLYPOSIS COLI. CHROMOSOME 5; 5q22.2	99
1.20. ARAP3: ARFGAP WITH RHOGAP DOMAIN, ANKYRIN REPEAT, AND PF DOMAINS 3. CHROMOSOME 5; 5q31.3	100
1.21. ARHGEF28: RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 28. CHROMOSOME 5; 5q13.2	100
1.22. ARHGAP26: RHO GTPASE ACTIVATING PROTEIN 26. CHROMOSOME 5; 5q31.3	100
1.23. ARL10: ADP RIBOSYLATION FACTOR LIKE GTPASE 10. CHROMOSOME 5; 5q35.2	101
1.24. ARL14EPL: ADP RIBOSYLATION FACTOR LIKE GTPASE 14 EFFECTOR PROTEIN. CHROMOSOME 5; 5q23.1	101
1.25. ARL15: ADP RIBOSYLATION FACTOR LIKE GTPASE. CHROMOSOME 5; 5q11.2	101
1.26. ARRDC3: ARRESTIN DOMAIN CONTAINING 3. CHROMOSOME 5; 5q14.3	102
1.27. ATG10: AUTOPHAGY RELATED 10. CHROMOSOME 5; 5q14.1-q14.2	102
1.28. ATG12: AUTOPHAGY RELATED 12. CHROMOSOME 5; 5q22.3	103
1.29. ATOX1: ANTIOXIDANT 1 COPPER CHAPERONE. CHROMOSOME 5; 5q33.1	103
1.30. CAST: CALPASTATIN. CHROMOSOME 5; 5q15	104
1.31. CCNB1: CYCLIN B1. CHROMOSOME 5; 5q13.2	104
1.32. CCNG1: CYCLIN G1. CHROMOSOME 5; 5q34	104
1.33. CD74: CD74 MOLECULE. CHROMOSOME 5; 5q33.1	105
1.34. CDC25C: CELL DIVISION CYCLE 25. CHROMOSOME 5; 5q31.2	105
1.35. CDK7: CYCLIN-DEPENDENT KINASE 7. CHROMOSOME 5; 5q13.2	106
1.36. CDX1: CAUDAL TYPE HOMEODOMAIN 1. CHROMOSOME 5; 5q32	106
1.37. CLPTMIL: CLEFT LIP AND PALATE TRANSMEMBRANE PROTEIN 1-LIKE PROTEIN. CHROMOSOME 5 ; 5p15.33	106
1.38. CSF1R: COLONY STIMULATING FACTOR 1 RECEPTOR. CHROMOSOME 5; 5q32	107
1.39. CTNNA1: CATENIN ALPHA 1. CHROMOSOME 5; 5q31.2	107
1.40. CXCL14: C-X-C MOTIF CHEMOKINE LIGAND 14. CHROMOSOME 5; 5q31.1	108
1.41. DAB2: DAB ADAPTOR PROTEIN 2. CHROMOSOME 5; 5p13.1	108
1.42. DHFR: DIHYDROFOLATE REDUCTASE. CHROMOSOME 5; 5q14.1	108
1.43. DROSHA: DROSHA RIBONUCLEASE III. CHROMOSOME 5; 5p13.3	109
1.44. DUSP1: DUAL SPECIFICITY PHOSPHATASE 1. CHROMOSOME 5; 5q35.1	109

1.45. EBF1: EBF TRANSCRIPTION FACTOR 1. CHROMOSOME 5; 5q33.3	110
1.46. EGR1: EARLY GROWTH RESPONSE 1. CHROMOSOME 5; 5q31.2	110
1.47. FAT2: FAT ATYPICAL CADHERIN 2. CHROMOSOME 5; 5q33.1	110
1.48. FER: FER TYROSINE KINASE. CHROMOSOME 5 ; 5q21.3	111
1.49. FGF1: FIBROBLAST GROWTH FACTOR 1. CHROMOSOME 5; 5q31	111
1.50. FGF10: FIBROBLAST GROWTH FACTOR 10. CHROMOSOME 5; 5p12	111
1.51. FGFR4: FIBROBLAST GROWTH FACTOR RECEPTOR 4. CHROMOSOME 5; 5q35.2	112
1.52. FLT4: FMS-RELATED RECEPTOR TYROSINE KINASE 4. CHROMOSOME 5; 5q35.3	112
1.53. GDNF: GLIAL CELL-DERIVED NEUROTROPHIC FACTOR. CHROMOSOME 5; 5p13.2	112
1.54. GPX3: GLUTATHIONE PEROXIDASE 3. CHROMOSOME 5; 5q33.1	113
1.55. HAVCR2: HEPATITIS A VIRUS CELLULAR RECEPTOR 2. CHROMOSOME 5; 5q33.3	113
1.56. HBEGF: HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. CHROMOSOME 5; 5q31.3	114
1.57. HDAC3: HISTONE DEACETYLASE 3. CHROMOSOME 5; 5q31.3	114
1.58. HINT1: HISTIDINE TRIAD NUCLEOTIDE-BINDING PROTEIN 1. CHROMOSOME 5; 5q23.3	114
1.59. HMMR: HYALURONAN-MEDIATED MOTILITY RECEPTOR. CHROMOSOME 5; 5q34	115
1.60. IL12B: INTERLEUKIN 12B. CHROMOSOME 5 ; 5q33.3	115
1.61. IL13: INTERLEUKIN 13. CHROMOSOME 5 ; 5q31.1	116
1.62. IL4: INTERLEUKIN 4. CHROMOSOME 5; 5q31.1	116
1.63. IL6ST: INTERLEUKIN 6 SIGNAL TRANSDUCER. CHROMOSOME 5; 5q11.2	116
1.64. IL7R: INTERLEUKIN 7 RECEPTOR. CHROMOSOME 5; 5p13.2	117
1.65. IRF1: INTERFERON REGULATORY FACTOR 1. CHROMOSOME 5; 5q31.1	117
1.66. ITGA1: INTEGRIN SUBUNIT ALPHA 1. CHROMOSOME 5; 5q11.2	117
1.67. ITK: IL2 INDUCIBLE T CELL KINASE. CHROMOSOME 5; 5q33.3	118
1.68. LIFR: LIF RECEPTOR SUBUNIT ALPHA. CHROMOSOME 5; 5p13.1	118
1.69. LOX: LYSYL OXIDASE. CHROMOSOME 5; 5q23.1	118
1.70. MAML1: MASTERMIND-LIKE TRANSCRIPTIONAL COACTIVATOR 1. CHROMOSOME 5; 5q35.3	119
1.71. MAP3K1: MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 1. CHROMOSOME 5; 5q11.2	119
1.72. MCC: MCC REGULATOR OF WNT SIGNALING PATHWAY. CHROMOSOME 5; 5q22.2	119
1.73. MEF2C: MYOCYTE ENHANCER FACTOR 2C. CHROMOSOME 5; 5q14.3	120
1.74. MTRR: 5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE METHYLTRANSFERASE REDUCTASE. CHROMOSOME 5; 5q15.31	120
1.75. NEUROG1: NEUROGENIN 1. CHROMOSOME 5 ; 5q14.3	120
1.76. NSD1: NUCLEAR RECEPTOR BINDING SET DOMAIN PROTEIN 1. CHROMOSOME 5; 5q35.3	120
1.77. PITX1: PAIRED LIKE HOMEODOMAIN 1. CHROMOSOME 5; 5q35.3	121
1.78. PDGFRB: PLATELET-DERIVED GROWTH FACTOR RECEPTOR BETA. CHROMOSOME 5; 5q32	121
1.79. PLK2: POLO-LIKE KINASE 2. CHROMOSOME 5; 5q11.2	121
1.80. POLK: DNA POLYMERASE KAPPA. CHROMOSOME 5; 5q13.3	122
1.81. PTTG1: PTTG1 REGULATOR OF SISTER CHROMATID SEPARATION, SECURING. CHROMOSOME 5; 5q33.3	122

1.82. PRLR: PROLACTIN RECEPTOR. CHROMOSOME 5; 5p13.2	122
1.83. RAD50: RAD50 DOUBLE STRAND BREAK REPAIR PROTEIN. CHROMOSOME 5; 5q31.1	123
1.84. RICTOR: RPTOR INDEPENDENT COMPANION OF MTOR COMPLEX 2. CHROMOSOME 5 ; 5p13.1	123
1.85. RACK1: RECEPTOR FOR ACTIVATED C KINASE 1. CHROMOSOME 5; 5q35.3	123
1.86. SPRY4: SPROUTY RTK SIGNALING ANTAGONIST 4. CHROMOSOME 5; 5q31.3	124
1.87. SDHA: SUCCINATE DEHYDROGENASE COMPLEX FLAVOPROTEIN SUBUNIT A. CHROMOSOME 5 ; 5p15.33	124
1.88. SELENOP: SELENOPROTEIN P. CHROMOSOME 5 ; 5p12	124
1.89. SKP1: S-PHASE KINASE-ASSOCIATED PROTEIN 1. CHROMOSOME 5; 5q31.1	125
1.90. SMAD5: SMAD FAMILY MEMBER 5. CHROMOSOME 5; 5q31.1	125
1.91. SPARC: SECRETED PROTEIN ACIDIC AND CYSTEINE-RICH. CHROMOSOME 5; 5q33.1	125
1.92. SPINK1: SERINE PEPTIDASE INHIBITOR KAZAL TYPE 1. CHROMOSOME 5; 5q32	126
1.93. TCF7: TRANSCRIPTION FACTOR 7. CHROMOSOME 5; 5q31.1	126
1.94. TERT: TELOMERASE REVERSE TRANSCRIPTASE. CHROMOSOME 5 ; 5p15.33	126
1.95. TGFBI: TRANSFORMING GROWTH FACTOR BETA-INDUCED. CHROMOSOME 5; 5q31.1	127
1.96. TLX3: T CELL LEUKEMIA HOMEBOX 3. CHROMOSOME 5; 5q35.1	127
1.97. TRIO: TRIO RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR. CHROMOSOME 5; 5p15.2	127
1.98. VCAN: VERSICAN. CHROMOSOME 5; 5Q14.2-q14.3	128
1.99. XRCC4: X-RAY REPAIR CROSS-COMPLEMENTING 4. CHROMOSOME 5; 5q14.2	128
CONCLUSION	128
REFERENCES	128

CHAPTER 6 CHROMOSOME 6 159

Shivani Singh, Saurav Panicker and Satish Ramalingam

1.1. GENE- AFDN; AF-6; AFADIN, ADHERENS JUNCTION FORMATION FACTOR LOCATION: 6P27	160
1.1.1. The Disease of Relevance	160
1.2. GENE- DEK; DEK PROTO-ONCOGENE LOCATION: 6p22.3	161
1.2.1. The Disease of Relevance	162
1.3. GENE: ROS1, ROS PROTO-ONCOGENE 1, RECEPTOR TYROSINE KINASE LOCATION: 6q22.1	162
1.3.1. The Disease of Relevance	163
1.4. GENE: CCND3, CYCLIN D3 LOCATION: 6p21.1	164
1.4.1. The Disease of Relevance:	165
1.5. GENE: CCN2, CELLULAR COMMUNICATION NETWORK FACTOR 2, CTGF LOCATION: 6q23.2	165
1.5.1. The Disease of Relevance:	166
1.6. GENE: GOPC, GOLGI-ASSOCIATED PDZ, AND COILED-COIL MOTIF-CONTAINING PROTEIN, FIG LOCATION: 6q22.1	167
1.6.1. The Disease of R Elevance:	167
1.7. GENE: MAP3K5, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 5 LOCATION: 6q23.3	167
1.7.1. The Disease of Relevance:	168
1.8. GENE: FOXC1, FORKHEAD BOX C1 LOCATION: 6p25.3	168

1.8.1. The Disease of Relevance:	168
1.9. GENE: FGFR1OP, FGFR1 ONCOGENE PARTNER LOCATION: 6q27	170
1.9.1. The Disease of Relevance:	170
1.10. GENE: IGF2R, INSULIN-LIKE GROWTH FACTOR 2 RECEPTOR LOCATION: 6q25.3	171
1.10.1. The Disease of Relevance	171
1.11. GENE: AIM1, ABSENT IN MELANOMA, CRYBG1 LOCATION: 6q21	172
1.11.1. The Disease of Relevance:	172
1.12. GENE: HACE1, HECT DOMAIN, AND ANKYRIN REPEAT-CONTAINING E3 UBIQUITIN-PROTEIN LIGASE 1 LOCATION: 6q16.3	172
1.12.1. The Disease of Relevance:	173
1.13. GENE: RIPK1, RECEPTOR-INTERACTING SERINE/THREONINE KINASE 1 LOCATION: 6p25.2	173
1.13.1. The Disease of Relevance:	173
1.14. GENE: THSB2, THROMBOSPONDIN 2 LOCATION: 6q27	174
1.14.1. The Disease of Relevance:	174
1.15. GENE: PTPRK, PROTEIN TYROSINE PHOSPHATASE RECEPTOR TYPE K LOCATION: 6q22.33	175
1.15.1. The Disease of Relevance:	176
1.16. GENE: HSP90AB1; HEAT SHOCK PROTEIN 90 ALPHA FAMILY CLASS B MEMBER 1 LOCATION: 6p21.1	176
1.16.1. The Disease of Relevance:	177
1.17. GENE: IRF4, INTERFERON REGULATORY FACTOR 4 LOCATION: 6p25.3	177
1.17.1. The Disease of Relevance:	178
1.18. GENE: VIP, VASOACTIVE INTESTINAL PEPTIDE LOCATION: 6q25.2	179
1.18.1. The Disease of Relevance:	179
1.19. GENE: HMGA1, HIGH MOBILITY GROUP AT-HOOK 1 LOCATION: 6p21.31	181
1.19.1. The Disease of Relevance:	181
1.20. GENE: MYB, MYB PROTO-ONCOGENE LOCATION: 6q23.3	182
1.20.1. The Disease of Relevance:	183
1.21. GENE: TNF, TUMOR NECROSIS FACTOR, TNF-ALPHA LOCATION: 6p21.33	184
1.21.1. The Disease of Relevance:	184
1.22. GENE: SRSF3, SERINE AND ARGININE-RICH SPLICING FACTOR 3 LOCATION: 6p21.31-p21.2	185
1.22.1. The Disease of Relevance:	186
1.23. GENE: CD24, CD24 ZMOLECULE LOCATION: 6q21	187
1.23.1. The Disease of Relevance:	187
1.24. GENE: VEGFA, VASCULAR ENDOTHELIAL GROWTH FACTOR A LOCATION: 6p21.1	188
1.24.1. The Disease of Relevance:	189
1.25. GENE: LTA, LYMPHOTOXIN A LOCATION: 6p21.33	189
1.25.1. The Disease of Relevance:	190
1.26. GENE: LIN28B, LIN-28 HOMOLOG B LOCATION: 6q16.3-q21	191
1.26.1. The Disease of Relevance:	191
1.27. GENE: LTB, LYMPHOTOXIN BETA LOCATION: 6p21.33	192
1.27.1. The Disease of Relevance:	192
1.28. GENE: LATS1, LARGE TUMOR SUPPRESSOR KINASE 1 LOCATION: 6q25.1	193
1.28.1. The Disease of Relevance:	193
1.29. GENE: IL17A, INTERLEUKIN 17A LOCATION: 6p12.2	193
1.29.1. The Disease of Relevance:	194
1.30. GENE 30: SOX4, SRY-BOX TRANSCRIPTION FACTOR 4 LOCATION: 6p22.3	194

1.30.1. The Disease of Relevance:	195
1.31. GENE: ESR1; ESTROGEN RECEPTOR 1, ER LOCATION: 6q25.1-Q25.2	196
1.31.1. The Disease of Relevance:	196
1.32. Gene: CDKN1A, Cyclin Dependent Kinase Inhibitor 1A, P21 Location: 6p21.2	197
1.32.1. The Disease of Relevance:	198
1.33. GENE: TRIM27. TRIPARTITE MOT6IF CONTAINING 27 LOCATION: 6p22.1	199
1.31.1. The Disease of Relevance:	199
1.34. GENE: PLAGL1; PLAG1 LIKE ZINC FINGER 1 LOCATION: 6q24.2	200
1.34.1. The Disease of Relevance:	200
1.35. GENE: NOTCH4; NOTCH RECEPTOR 4 LOCATION: 6p21.32	201
1.35.1. The Disease of Relevance:	201
1.36. GENE: NEDD9; NEURAL PRECURSOR CELL EXPRESSED, DEVELOPMENTALLY DOWN-REGULATED 9 LOCATION: 6p24.2	202
1.36.1. Disease if Relevance:	202
1.37. GENE: MAPK14; MITOGEN ACTIVATED PROTEIN KINASE 14; p38 LOCATION: 6p21.31	203
1.37.1. The Disease of Relevance:	204
1.38. GENE: GSTA1; GLUTATHIONE S-TRANSFERASE ALPHA 1 LOCATION: 6p12.2	204
1.38.1. The Disease of Relevance:	204
39. GENE: GJA1; GAP JUNCTION PROTEIN ALPHA 1, CONNEXIN 43 [CX43] LOCATION: 6q22.31	205
1.39.1. The Disease of Relevance:	206
1.40. GENE: DAXX, DEATH DOMAIN-ASSOCIATED PROTEIN LOCATION: 6p21.32	207
1.40.1. The Disease of Relevance	207
CONCLUSION	208
REFERENCES	209

CHAPTER 7 CHROMOSOME 7 223

Muthu Vijai Bharath Vairamani, Harini Hariharan and Satish Ramalingam

1.1. ABCB5 - ATP BINDING CASSETTE SUBFAMILY B MEMBER 5 LOCATION: CHROMOSOME 7; 7p21.1	223
1.2. ACTB – ACTIN BETA LOCATION: CHROMOSOME 7; 7p22.1	224
1.3. AGR2 - ANTERIOR GRADIENT 2 LOCATION: CHROMOSOME 7; 7p21.1	224
1.4. AKAP9 - A-KINASE ANCHORING PROTEIN 9 LOCATION: CHROMOSOME 7; 7q21.2	224
1.5. AMPH – AMPHIPHYSIN LOCATION: CHROMOSOME 7; 7p14.1	224
1.6. AQP1 - AQUAPORIN 1 LOCATION: CHROMOSOME 7; 7p14.3	224
1.7. BRAF - B-RAF PROTO-ONCOGENE, SERINE/THREONINE KINASE LOCATION: CHROMOSOME 7; 7q34	225
1.8. CARD11 - CASPASE RECRUITMENT DOMAIN FAMILY MEMBER 11 LOCATION: CHROMOSOME 7; 7p22.2	225
1.9. CCM2 - CCM2 SCAFFOLD PROTEIN LOCATION: CHROMOSOME 7; 7p13	225
1.10. CDK6 - CYCLIN-DEPENDENT KINASE 6 LOCATION: CHROMOSOME 7; 7q21.2	226
1.11. CREB3L2 - CAMP RESPONSIVE ELEMENT BINDING PROTEIN THREE LIKE 2 LOCATION: CHROMOSOME 7; 7q33	227
1.12. CUX1 - CUT LIKE HOMEBOX 1 LOCATION: CHROMOSOME 7; 7q22.1	227
1.13. EGFR - EPIDERMAL GROWTH FACTOR RECEPTOR LOCATION: CHROMOSOME 7; 7p11.2	227
1.14. ELN – ELASTIN LOCATION: CHROMOSOME 7; 7q11.23	227
1.15. ETV1 - ETS VARIANT TRANSCRIPTION FACTOR 1 LOCATION: CHROMOSOME 7; 7p21.2	227

1.16. EZH2 - ENHANCER OF ZESTE 2 POLYCOMB REPRESSIVE COMPLEX 2	
SUBUNIT LOCATION: CHROMOSOME 7; 7q36.1	228
1.17. GLI3 - GLI FAMILY ZINC FINGER 3 LOCATION: CHROMOSOME 7; 7p14.1	228
1.18. HIP1 - HUNTINGTIN INTERACTING PROTEIN 1 LOCATION: CHROMOSOME 7; 7q11.23	228
1.19. HNRNPA2B1 - HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A2/B1 LOCATION: CHROMOSOME 7; 7p15.2	228
1.20. HOXA1 - HOMEBOX A1 LOCATION: CHROMOSOME 7; 7p15.2	229
1.21. HOXA4 - HOMEBOX A4 LOCATION: CHROMOSOME 7; 7p15.2	229
1.22. HOXA5 - HOMEBOX A5 LOCATION: CHROMOSOME 7; 7p15.2	229
1.23. IGFBP1 - INSULININSULIN-LIKE FACTOR BINDING PROTEIN 1 LOCATION: CHROMOSOME 7; 7p12.3	229
1.24. IGFBP3 - INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3 LOCATION: CHROMOSOME 7; 7p12.3	230
1.25. IL6 - INTERLEUKIN 6 LOCATION: CHROMOSOME 7; 7p15.3	230
1.26. INHBA - INHIBIN SUBUNIT BETA A LOCATION: CHROMOSOME 7; 7p14.1	230
1.27. JAZF1 - JAZF ZINC FINGER 1 LOCATION: CHROMOSOME 7; 7P15.2-p15.1	231
1.28. KIAA1549 - KIAA1549 PROTEIN LOCATION: CHROMOSOME 7; 7q34	231
1.29. MACC1 - MET TRANSCRIPTIONAL REGULATOR MACC1 LOCATION: CHROMOSOME 7; 7p21.1	231
1.30. MET - MET PROTO-ONCOGENE, RECEPTOR TYROSINE KINASE LOCATION: CHROMOSOME 7; 7q31.2	231
1.31. MNX1 - MOTOR NEURON AND PANCREAS HOMEBOX 1 LOCATION: CHROMOSOME 7; 7q36.3	232
1.32. PMS2 - PMS1 HOMOLOG 2, MISMATCH REPAIR SYSTEM COMPONENT LOCATION: CHROMOSOME 7; 7p22.1	232
1.33. RAC1 - RAC FAMILY SMALL GTPASE 1 LOCATION: CHROMOSOME 7; 7p22.1	232
1.34. RALA - RAS LIKE PROTO-ONCOGENE A LOCATION: CHROMOSOME 7; 7p14.1	232
1.35. SBDS - SBDS RIBOSOME MATURATION FACTOR LOCATION: CHROMOSOME 7; 7q11.21	233
1.36. SEPT7 - SEPTIN 7 LOCATION: CHROMOSOME 7; 7p14.2	233
1.37. SMO - SMOOTHENED, FRIZZLED CLASS RECEPTOR LOCATION: CHROMOSOME 7; 7q32.1	233
1.38. TES - TESTIN LIM DOMAIN PROTEIN LOCATION: CHROMOSOME 7; 7q31.2	234
1.39. TRIM24 - TRIPARTITE MOTIF-CONTAINING 24 LOCATION: CHROMOSOME 7; 7q33-q34	234
1.40. TWIST1 - TWIST FAMILY BHLH TRANSCRIPTION FACTOR 1 LOCATION: CHROMOSOME 7; 7p21.1	234
CONCLUSION	234
REFERENCES	235

CHAPTER 8 CHROMOSOME 8

Muthu Vijai Bharat Vairamani, Harini Hariharan and Satish Ramalingam

1.1. ADAM28: ADAM METALLOPEPTIDASE DOMAIN 28 CHROMOSOME 8; 8p21.2	243
1.2. ADAM32: ADAM METALLOPEPTIDASE DOMAIN 32 CHROMOSOME 8; 8p11.22	244
1.3. ADAM7: ADAM METALLOPEPTIDASE DOMAIN 7 CHROMOSOME 8; 8p21.2	244
1.4. ADAM9: ADAM METALLOPEPTIDASE DOMAIN 9 CHROMOSOME 8; 8p11.22 ...	244
1.5. ADGRB1: ADHESION G PROTEIN-COUPLED RECEPTOR B1 CHROMOSOME 8; 8q24.3	245

1.6. ADHFE1: ALCOHOL DEHYDROGENASE IRON CONTAINING 1 CHROMOSOME 8; 8q13.1	245
1.7. AGO2: ARGONAUTE RISC CATALYTIC COMPONENT 2 CHROMOSOME 8; 8q24.3	245
1.8. ANGPT1: ANGIOPOIETIN 1 CHROMOSOME 8; 8q23.1	246
1.9. ANGPT2: ANGIOPOIETIN 2 CHROMOSOME 8; 8p23.1	246
1.10. ANK1: ANKYRIN 1 CHROMOSOME 8; 8p11.21	246
1.11. ANKRD46: ANKYRIN REPEAT DOMAIN 46 CHROMOSOME 8; 8q22.3	247
1.12. ANXA13: ANNEXIN A13 CHROMOSOME 8; 8q24.13	247
1.13. ARC: ACTIVITY REGULATED CYTOSKELETON ASSOCIATED PROTEIN CHROMOSOME 8; 8q24.3	247
1.14. ARFGEF1: ADP RIBOSYLATION FACTOR GUANINE NUCLEOTIDE EXCHANGE FACTOR 1 CHROMOSOME 8; 8q13.2	247
1.15. ARHGEF10: RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 10 CHROMOSOME 8; 8p23.3	248
1.16. ASAH1: N-ACYLSPHINGOSINE AMIDOHYDROLASE 1 CHROMOSOME 8; 8p22	248
1.17. ASAP1: ARFGAP WITH SH3 DOMAIN, ANKYRIN REPEAT, AND PH DOMAIN 1 CHROMOSOME 8; 8Q24.21-q24.22	248
1.18. ASH2L: ASH2-LIKE, HISTONE LYSINE METHYLTRANSFERASE COMPLEX SUBUNIT CHROMOSOME 8; 8p11.23	249
1.19. ASPH: ASPARTATE BETA-HYDROXYLASE CHROMOSOME 8; 8q12.3	250
1.20. ATAD2: ATPASE FAMILY AAA DOMAIN CONTAINING 2 CHROMOSOME 8; 8q24.13	250
1.21. ATP6V0D2: ATPASE H+ TRANSPORTING V0 SUBUNIT D2 CHROMOSOME 8; 8q21.3	250
1.22. ATP6V1B2: ATPASE H+ TRANSPORTING V1 SUBUNIT B2 CHROMOSOME 8; 8p21.3	250
1.23. ATP6V1C1: ATPASE H+ TRANSPORTING V1 SUBUNIT C1 CHROMOSOME 8; 8q22.3	251
1.24. AZIN1: ANTIZYME INHIBITOR 1 CHROMOSOME 8; 8q22.3	251
1.25. BAALC: BAALC BINDER OF MAP3K1 AND KLF4 CHROMOSOME 8; 8q22.3	251
1.26. BLK: BLK PROTO-ONCOGENE, SRC FAMILY TYROSINE KINASE CHROMOSOME 8; 8p23.1	252
1.27. BNIP3L: BCL2 INTERACTING PROTEIN 3 LIKE CHROMOSOME 8; 8p21.27	252
1.28. CCDC26: CCDC26 LONG NON-CODING RNA CHROMOSOME 8; 8q24.21	252
1.29. CCNE2: CYCLIN NE2 CHROMOSOME 8; 8q22.1	252
1.30. CDH17: CADHERIN 17 CHROMOSOME 8; 8q22.1	253
1.31. CEBPD: CCAAT ENHANCER BINDING PROTEIN DELTA CHROMOSOME 8; 8q11.21	253
1.32. CLU: CLUSTERIN CHROMOSOME 8; 8p21.1	253
1.33. COPS5: COP9 SIGNALOSOME SUBUNIT 5 CHROMOSOME 8; 8q13.1	254
1.34. COX6C: CYTOCHROME C OXIDASE SUBUNIT 6C CHROMOSOME 8; 8q22.2	254
1.35. CTSB: CATHEPSIN B CHROMOSOME 8; 8p23.1	254
1.36. DLC1: DLC1 RHO GTPASE ACTIVATING PROTEIN CHROMOSOME 8; 8p22	254
1.37. DOK2: DOCKING PROTEIN 2 CHROMOSOME 8; 8p21.3	255
1.38. DUSP4: DUAL SPECIFICITY PHOSPHATASE 4 CHROMOSOME 8; 8p12	255
1.39. E2F5: E2F TRANSCRIPTION FACTOR 5 CHROMOSOME 8; 8q21.2	255
1.40. EBAG9: ESTROGEN RECEPTOR BINDING SITE ASSOCIATED ANTIGEN 9 CHROMOSOME 8; 8q23.2	256
1.41. EIF3E: EUKARYOTIC TRANSLATION INITIATION FACTOR 3 SUBUNIT E CHROMOSOME 8; 8q23.1	256

1.42. EXT1: EXOSTOSIN GLYCOSYLTRANSFERASE 1 CHROMOSOME 8; 8q24.11	256
1.43. FABP5: FATTY ACID BINDING PROTEIN 5 CHROMOSOME 8; 8q21.13	256
1.44. FGFR1: FIBROBLAST GROWTH FACTOR RECEPTOR 1 CHROMOSOME 8; 8p11.23	257
1.45. GATA4: GATA BINDING PROTEIN 4 CHROMOSOME 8; 8p23.1	257
1.46. HAS2: HYALURONAN SYNTHASE 2 CHROMOSOME 8; 8q24.13	257
1.47. HEY1: HE'S A RELATED FAMILY BHLH TRANSCRIPTION FACTOR WITH YRPW MOTIF 1 CHROMOSOME 8; 8q21.13	258
1.48. HSF1: HEAT SHOCK TRANSCRIPTION FACTOR 1 CHROMOSOME 8; 8q24.3	258
1.49. IDO1: INDOLEAMINE 2,3-DIOXYGENASE 1 CHROMOSOME 8; 8p11.21	258
1.50. IKBKB: INHIBITOR OF NUCLEAR FACTOR KAPPA B KINASE SUBUNIT BETA CHROMOSOME 8; 8p11.21	259
1.51. IL7: INTERLEUKIN 7 CHROMOSOME 8; 8q21.13	259
1.52. KAT6A: LYSINE ACETYLTRANSFERASE 6A CHROMOSOME 8; 8p11.21	259
1.53. LOXL2: LYSYL OXIDASE-LIKE 2 CHROMOSOME 8; 8p21.3	260
1.54. LYN: LYN PROTO-ONCOGENE, SRC FAMILY TYROSINE KINASE CHROMOSOME 8; 8q12.1	260
1.55. LZTS1: LEUCINE ZIPPER TUMOR SUPPRESSOR 1 CHROMOSOME 8; 8p21.3	260
1.56. MCM4: MINICHROMOSOME MAINTENANCE COMPLEX COMPONENT 4 CHROMOSOME 8; 8q11.21	260
1.57. MIR124-1: MICRORNA 124-1 CHROMOSOME 8; 8p23.1	261
1.58. MOS: MOS PROTO-ONCOGENE, SERINE/THREONINE KINASE CHROMOSOME 8; 8q12.1	261
1.59. MSR1: MACROPHAGE SCAVENGER RECEPTOR 1 CHROMOSOME 8; 8p22	261
1.60. MTDH: METADHERIN CHROMOSOME 8; 8q22.1	261
1.61. MTSS1: MTSS I-BAR DOMAIN CONTAINING 1 CHROMOSOME 8; 8q24.13	262
1.62. MYC: MYC PROTO-ONCOGENE, BHLH TRANSCRIPTION FACTOR CHROMOSOME 8; 8q24.21	262
1.63. NAT1: N-ACETYLTRANSFERASE 1 CHROMOSOME 8; 8p22	262
1.64. NAT2: N-ACETYLTRANSFERASE 2 CHROMOSOME 8; 8p22	263
1.65. NBN: NIBRIN CHROMOSOME 8; 8q21.3	263
1.66. NCOA2: NUCLEAR RECEPTOR COACTIVATOR 2 CHROMOSOME 8; 8q13.3	263
1.67. NDRG1: N-MYC DOWNSTREAM REGULATED 1 CHROMOSOME 8; 8q24.22	263
1.68. NEFL: NEUROFILAMENT LIGHT CHROMOSOME 8; 8p21.2	264
1.69. CCN3: CELLULAR COMMUNICATION NETWORK FACTOR 3 CHROMOSOME 8; 8q24.12	264
1.70. NRG1: NEUREGULIN 1 CHROMOSOME 8; 8p12	264
1.71. NSD3: NUCLEAR RECEPTOR BINDING SET DOMAIN PROTEIN 3 CHROMOSOME 8; 8p11.23	264
1.72. PCM1: PERICENTRIOLAR MATERIAL 1 CHROMOSOME 8; 8p22	265
1.73. PINX1: PIN2 [TERF1] INTERACTING TELOMERASE INHIBITOR 1 CHROMOSOME 8; 8p23.1	265
1.74. PLAG1: PLEOMORPHIC ADENOMA G1 ZINC FINGER CHROMOSOME 8; 8q12.1	265
1.75. PLAT: PLASMINOGEN ACTIVATOR, TISSUE TYPE CHROMOSOME 8; 8p11.21	265
1.76. POLB: DNA POLYMERASE BETA CHROMOSOME 8; 8p11.21	266
1.77. PRKDC: PROTEIN KINASE, DNA-ACTIVATED, CATALYTIC SUBUNIT CHROMOSOME 8; 8q11.21	266
1.78. PSCA: PROSTATE STEM CELL ANTIGEN CHROMOSOME 8; 8q24.3	266
1.79. PTK2: PROTEIN TYROSINE KINASE 2 CHROMOSOME 8; 8q24.3	267
1.80. PTP4A3: PROTEIN TYROSINE PHOSPHATASE 4A3 CHROMOSOME 8; 8q24.3	267

CONCLUSION	267
REFERENCES	267
CHAPTER 9 CHROMOSOME 9	287
<i>Thilaga Thirugnanam, Yamini Chandrapraksh, Sivasankari Ramadurai, Abhishek Mitra, Ravi Gor, Saurav Panicker and Satish Ramalingam</i>	
1.1. ABCA1 - ATP-BINDING CASSETTE, SUBFAMILY A, MEMBER 1 CHROMOSOME 9; 9q31.1	287
1.2. ANXA1 - ANNEXIN A1 CHROMOSOME 9; 9q21.13	288
1.3. AQP3 - AQUAPORIN 3 CHROMOSOME 9; 9p13.3	288
1.4. BAG1 - BCL2- ASSOCIATED ANTHANOGENE 1 CHROMOSOME 9; 9p13.3	288
1.5. BRINP1 - BONE MORPHOGENETIC PROTEIN/RETINOIC ACID-INDUCIBLE NEURAL-SPECIFIC PROTEIN 1 CHROMOSOME 9; 9q33.1	289
1.6. CA9 - CARBONIC ANHYDRASE 9 CHROMOSOME 9; 9p13.3	289
1.7. CCL19 - C-C MOTIF CHEMOKINE LIGAND 19 CHROMOSOME 9; 9p13.3	289
1.8. CCL21 - C-C MOTIF CHEMOKINE LIGAND 21 CHROMOSOME 9; 9p13.3	289
1.9. CD274 - MOLECULE PROGRAMMED CELL DEATH 1 LIGAND 1 CHROMOSOME 9; 9p24.1	289
1.10. CDK9 - CYCLIN-DEPENDENT KINASE 9 CHROMOSOME 9; 9q34.11	290
1.11. CDKN2B - CYCLIN-DEPENDENT KINASE INHIBITOR 2B CHROMOSOME 9; 9p21.3	290
1.12. CDKN2B-AS1- CDKN2B ANTISENSE RNA 1 CHROMOSOME 9; 9p21.3	290
1.13. CKS2 - CDC28 PROTEIN KINASE REGULATORY SUBUNIT 2 CHROMOSOME 9; 9q22.2	291
1.14. DAB2IP - DAB2 INTERACTING PROTEIN CHROMOSOME 9; 9q33.2	291
1.15. DAPK1-DEATH-ASSOCIATED PROTEIN KINASE 1 CHROMOSOME 9; 9q21.33	291
1.16. DEC1- DELETED IN ESOPHAGEAL CANCER 1 CHROMOSOME 9; 9q33.1	292
1.17. FOXE1- FORKHEAD BOX E1 CHROMOSOME 9; 9q22.33	292
1.18. GALT - GALACTOSE-1-PHOSPHATE URIDYLTRANSFERASE CHROMOSOME 9; 9p13.3	292
1.19. GAS1 - GROWTH ARREST-SPECIFIC 1 CHROMOSOME 9; 9q21.33	292
1.20. JAK2 - JANUS KINASE 2 CHROMOSOME 9; 9p24.1	293
1.21. KDM4C - KYSINE DEMETHYLASE 4C CHROMOSOME 9; 9p24.1	294
1.22. LCN2 - LIPOCALIN 2 CHROMOSOME 9; 9q34.11	294
1.23. MELK - MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE CHROMOSOME 9; 9p13.2	294
1.24. MLANA - MELAN-A CHROMOSOME 9; 9p24.1	294
1.25. MLLT3 - SUPER ELONGATION COMPLEX SUBUNIT CHROMO SOME 9; 9p 21.3	295
1.26. MTAP - METHYL THIO ADENOSINE PHOSPHORYLASE CHROMO SOME 9; 9p 21.3	295
1.27. NFIB - NUCLEAR FACTOR I B CHROMOSOME 9; 9P23-p22.3	295
1.28. NOTCH1 - NOTCH RECEPTOR 1 CHROMOSOME 9; 9q34.3	295
1.29. NR4A3 - NUCLEAR RECEPTOR SUBFAMILY 4 GROUP A MEMBER 3 CHROMOSOME 9; 9q31.1	296
1.30. NUP214 - NUCLEOPORIN 214 CHROMOSOME 9; 9q34.13	296
1.31. PAX5 - PAIRED BOX 5 CHROMOSOME 9; 9p13.2	296
1.32. PBX3 - PBX HOMEBOX 3 CHROMOSOME 9; 9q33.3	296
1.33. PCA3 - PROSTATE CANCER-ASSOCIATED 3 CHROMOSOME 9; 9q21.2	297
1.34. PSIP1 - PC4 AND SFRS1 INTERACTING PROTEIN 1 CHROMOSOME 9; 9p22.3	297
1.35. PTCH1 - PATCHED 1 CHROMOSOME 9; 9q22.32	297

1.58. NODAL: NODAL GROWTH DIFFERENTIATION FACTOR CHROMOSOME 10; 10q22.1	329
1.59. PRINS: PSORIASIS-ASSOCIATED NON-PROTEIN CODING RNA INDUCED BY STRESS CHROMOSOME 10; 10p12.1	329
1.60. VIM: VIMENTIN CHROMOSOME 10; 10p13	329
1.61. MAPK8: MITOGEN-ACTIVATED PROTEIN KINASE 8/ JNK1 CHROMOSOME 10; 10q11.22	330
1.62. PAX2: PAIRED BOX 2 CHROMOSOME 10; 10q24.31	330
1.63. TCF7L2: TRANSCRIPTION FACTOR 7 LIKE 2: CHROMOSOME 10; 10Q25.2-q 25.3	330
1.64. TET1: TET-METHYLCYTOSINE DIOXYGENASE 1 /TEN ELEVEN TRANSLOCATION CHROMOSOME 10; 10q21.3	330
1.65. KLF6: KRUPPEL-LIKE FACTOR 6 CHROMOSOME 10; 10p15.2	331
1.66. MLLT10: MLLT10 HISTONE LYSINE METHYLTRANSFERASE DOT1L COFACTOR CHROMOSOME 10 ; 10p12.31	331
1.67. MGMT: O-6-METHYLGUANINE-DNA METHYLTRANSFERASE CHROMOSOME 10; 10q26.3	331
1.68. BAG3: BCL-2 ASSOCIATED ATHANOGENE 3 CHROMOSOME 10; 10q26.11	332
1.69. BTRC: BETA-TRANSDUCIN REPEAT CONTAINING E3 UBIQUITIN PROTEIN LIGASE CHROMOSOME 10; 10q24.32	332
1.70. POLL: DNA POLYMERASE LAMBDA CHROMOSOME 10; 10q24.32	332
CONCLUSION	332
REFERENCES	333

CHAPTER 11 CHROMOSOME 11 344

Harini Hariharan, Saurav Panicker and Satish Ramalingam

1.1. GENE - NUP98; NUCLEOPORIN 98. LOCATION - 11p15.4.	344
1.2. GENE - CCND1; CYCLIN D1 LOCATION - 11q13.3	345
1.3. GENE -BIRC3; BACULOVIRAL-IAP REPEAT CONTAINING-3. LOCATION - 11q22.2	346
1.4. GENE - POU2AF1; POU-CLASS 2 HOMEBOX-ASSOCIATING FACTOR 1 LOCATION - 11q23.1	346
1.5. GENE -KMT2A; LYSINE-METHYLTRANSFERASE 2 A. LOCATION - 11q23.3.	347
1.6. GENE -CREB3L1; CAMP-RESPONSIVE ELEMENT-BINDING PROTEIN3 LIK1. LOCATION - 11p11.2	348
1.7. GENE - CARS1; CYSTEINYL-TRNA SYNTHETASE 1. LOCATION - 11p15.4	348
1.8. GENE - MALAT1; METASTASIS-ASSOCIATED LUNG ADENOCARCINOMA TRANSCRIPT 1. LOCATION - 11q13.1	349
1.9. GENE -NUMA1; NUCLEAR-MITOTIC APPARATUS PROTEIN1. LOCATION - 11q13.4	349
1.10. GENE - MAML2; MASTERMIND-LIKE TRANSCRIPTIONAL CO-ACTIVATOR2 LOCATION - 11q21	350
1.11. GENE -DDX10; DEAD BOX HELICASE10. LOCATION - 11q22.3	350
1.12. GENE - PCSK7; PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 7. LOCATION - 11q23.3	351
1.13. GENE - CBL; CBL PROTO-ONCOGENE. LOCATION - 11q23.3	351
1.14. GENE -ARHGEF12; RHO-GUANINE NUCLEOTIDE-EXCHANGE FACTOR12. LOCATION - 11q23.3.	352
1.15. GENE - RASSF5; RAS ASSOCIATION DOMAIN FAMILY MEMBER 5, LOCATION - 11q32.1	352
1.16. GENE -IGF2; INSULIN-LIKE GROWTH FACTOR 2. LOCATION - 11p15.5	353

1.17. GENE - WT1; WT1 TRANSCRIPTION FACTOR. LOCATION - 11p13.	353
1.18. GENE - HRAS; H-RAS PROTO-ONCOGENE, GTPASE. LOCATION - 11p15.5	353
1.19. GENE - MEN1; MENIN 1 LOCATION - 11q13.1	354
1.20. GENE -ATM; ATM-SERINE/THREONINE-KINASE. LOCATION - 11q22.3	354
1.21. GENE -SDHAF2; SUCCINATE-DEHYDROGENASE COMPLEX-ASSEMBLY FACTOR2 LOCATION - 11q12.2	355
1.22. GENE - BDNF; BRAIN-DERIVED NEUROTROPHIC FACTOR LOCATION - 11p14.1	355
1.23. GENE - CD44; CD44 MOLECULE (INDIAN BLOOD GROUP) LOCATION - 11p13	356
1.24. GENE - CD82; CD82 MOLECULE LOCATION - 11p11.2	356
1.25. GENE - NOX4 LOCATION - 11q14.3	356
1.26. GENE - CHEK1; CHECKPOINT KINASE 1. LOCATION - 11q24.2	357
1.27. GENE -STIM1; STROMAL-INTERACTION MOLECULE1. LOCATION - 11p15.4	357
1.28. GENE - CCKBR; CHOLECYSTOKININ B RECEPTOR LOCATION - 11p15.4	358
1.29. GENE - IFITM1; INTERFERON-INDUCED TRANSMEMBRANE PROTEIN 1 LOCATION - 11p15.5	358
1.30. GENE -MUC5AC; MUCIN5AC, OLIGOMERIC-MUCUS/GEL-FORMING. LOCATION - 11p15.5	358
1.31. GENE -MUC5B; MUCIN5B, OLIGOMERIC-MUCUS/GEL-FORMING. LOCATION - 11p15.5	358
1.32. GENE - FEN1; FLAP STRUCTURE-SPECIFIC ENDONUCLEASE LOCATION - 11q12.2	359
1.33. GENE - PLAAT4; PHOSPHOLIPASE A AND ACYLTRANSFERASE 4 OR RARRES3 (RETINOIC ACID RECEPTOR RESPONDER PROTEIN 3). LOCATION - 11q12.3	359
1.34. GENE- IGF2-AS; IGF2 ANTISENSE RNA LOCATION - 11p15.5	360
1.35. GENE -MS4A1; MEMBRANE-SPANNING 4-DOMAINS A1 LOCATION - 11q12.2	360
1.36. GENE -CD151; CD151-MOLECULE (RAPH BLOOD-GROUP) LOCATION - 11p15.5	360
1.37. GENE - CTSD; CATHEPSIN D LOCATION - 11p15.5	361
1.38. GENE - IL18; INTERLEUKIN 18 LOCATION - 11q23.1	361
1.39. GENE - DRD2; DOPAMINE-RECEPTORD2 LOCATION - 11q23.2	361
1.40. GENE -CLMP; CXADR-LIKE MEMBRANE PROTEIN LOCATION - 11q24.1	362
1.41. GENE -KCNQ1OT1; KCNQ1 OPPOSITE-STRAND/ANTISENSE TRANSCRIPT1 LOCATION - 11p15.5	362
CONCLUSION	363
REFERENCES	363

CHAPTER 12 CHROMOSOME 12 371

Yamini Chandraprakash, Ravi Gor, Saurav Panicker and Satish Ramalingam

1.1. A2M – ALPHA-2-MACROGLOBULIN, CHROMOSOME 12; 12p13.31	371
1.2. A2LM1 - ALPHA 2 MICROGLOBULIN LIKE 1 CHROMOSOME 12; 12p13.31	372
1.3. AACs-ACETOACETYL-COA SYNTHETASE CHROMOSOME 12; 12q24.31	372
1.4. ABCB9 - ATP-BINDING CASSETTE, SUBFAMILY B, MEMBER 9 CHROMOSOME 12; 12q24.31	372
1.5. ABCC9 - ATP-BINDING CASSETTE, SUBFAMILY C, MEMBER 9 CHROMOSOME 12; 12p12.1	372
1.6. ABCD2 - ATP-BINDING CASSETTE, SUBFAMILY 3, MEMBER 2 CHROMOSOME 12; 12q12	373
1.7. ACRBP - ACROSIN-BINDING PROTEIN CHROMOSOME 12; 12p13-p12	373

1.8. ACSS3 - ACYL-COA SYNTHETASE SHORT CHAIN FAMILY, MEMBER 3CHROMOSOME 12; 12q21.31	373
1.9. ACTR6 - ACTIN RELATED PROTEIN 6 CHROMOSOME 12; 12q23.1	374
1.10. ACVR1B - ACTIVIN A RECEPTOR, TYPE IB CHROMOSOME 12; 12q13.13	374
1.11. ACVRL1 - ACTIVIN A RECEPTOR, TYPE II-LIKE 1 CHROMOSOME 12;12q13.13	374
1.12. ADCY6 - ADENYLATE CYCLASE 6 CHROMOSOME 12; 12q13.12	374
1.13. ADGRD1 - ADHESION G PROTEIN-COUPLED RECEPTOR D1 CHROMOSOME 12; 12q24.33	375
1.14. ADIPOR2 - ADIPONECTIN RECEPTOR 2 CHROMOSOME 12;12p13.33	375
1.15. AEBP2 - AE-BINDING PROTEIN 2 CHROMOSOME 12; 12p12.3	376
1.16. AGAP2 - ARF GTPASE-ACTIVATING PROTEIN WITH GTPASE DOMAIN, ANKYRIN REPEAT, AND PLECKSTRIN HOMOLOGY DOMAIN 2 CHROMOSOME 12; 12q14.1	376
1.17. AICDA - ACTIVATION-INDUCED CYTIDINE DEAMINASE CHROMOSOME 12; 12p13.31	376
1.18. ALDH1L2 - ALDEHYDE DEHYDROGENASE 1 FAMILY, MEMBER L2 CHROMOSOME 12; 12q23.3	377
1.19. ALDH2 - ALDEHYDE DEHYDROGENASE 2 FAMILY CHROMOSOME 12;12q24.12	377
1.20. ALX1 - ARISTALESS-LIKE HOMEBOX 1 CHROMOSOME 12; 12q21.31	377
1.21. AMHR2 - ANTI-MULLERIAN HORMONE TYPE II RECEPTOR CHROMOSOME 12; 12q13.13	378
1.22. AMIGO2 - ADHESION MOLECULE WITH IG-LIKE DOMAIN 2 CHROMOSOME 12; 12q13.11	378
1.23. ANAPC7 - ANAPHASE-PROMOTING COMPLEX, SUBUNIT 7 CHROMOSOME 12; 12q24.11	378
1.24. ANKRD33 - ANKYRIN REPEAT DOMAIN 33 CHROMOSOME 12; 12q13.13	379
1.25. ANKRD52 - ANKYRIN REPEAT DOMAIN 52 CHROMOSOME 12; 12q13.3	379
1.26. ANKS1B - ANKYRIN REPEAT AND STERILE ALPHA MOTIF DOMAINS- CONTAINING PROTEIN 1B CHROMOSOME 12;12q23.1	379
1.27. ANO6 - ANOCTAMIN 6 CHROMOSOME 12; 12q12	380
1.28. APAF1 - APOPTOTIC PROTEASE ACTIVATING FACTOR 1 CHROMOSOME 12;12q23.1	380
1.29. APOBEC1 - APOLIPOPROTEIN B MRNA-EDITING ENZYME, CATALYTIC POLYPEPTIDE 1 CHROMOSOME 12;12p13.31	380
1.30. APOF - APOLIPOPROTEIN F CHROMOSOME 12; 12q13.3	381
1.31. APOLD1 -APOLIPOPROTEIN L DOMAIN-CONTAINING 1 CHROMOSOME 12; 12p13.1	381
1.32. APPL2 - ADAPTOR PROTEIN, PHOSPHOTYROSINE INTERACTION, PH DOMAIN, AND LEUCINE ZIPPER-CONTAINING PROTEIN 2 CHROMOSOME 12;12q23.3	381
1.33. AQP2 - AQUAPORIN 2 CHROMOSOME 12; 12q13.12	382
1.34. AQP5 - AQUAPORIN 5 CHROMOSOME 12;12q13.12	382
1.35. AQP6 - AQUAPORIN 6 CHROMOSOME 12; 12q13.12	382
1.36. ARF3 - ADP-RIBOSYLATION FACTOR 3 CHROMOSOME 12; 12q13.12	382
1.37. ARHGAP9 - RHO GTPASE-ACTIVATING PROTEIN 9 CHROMOSOME 12; 12q13.3	383
1.38. ARHGDI3 - RHO GDP-DISSOCIATION INHIBITOR BETA CHROMOSOME 12;12p12.3	383

1.39. ARID2 - AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 2	
CHROMOSOME 12;12q12	383
1.40. ARL1 - ADP-RIBOSYLATION FACTOR-LIKE 1 CHROMOSOME 12;12q23.2	384
1.41. ARNTL2 - ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR-LIKE PROTEIN CHROMOSOME 12;12p11.232	384
1.42. ARPC3 - ACTIN-RELATED PROTEIN 2/3 COMPLEX, SUBUNIT 3	
CHROMOSOME 12;12q24.11	384
1.43. ART4 - ADP-RIBOSYLTRANSFERASE 4 CHROMOSOME 12;12p12.3	384
1.44. ASB8 - ANKYRIN REPEAT- AND SOCS BOX-CONTAINING PROTEIN 8	
CHROMOSOME 12;12q13.11	385
1.45. ASCL1 - ACHAETE-SCUTE FAMILY BHLH TRANSCRIPTION FACTOR 1	
CHROMOSOME 12;12q23.2	385
1.46. ASCL4 - ACHAETE-SCUTE FAMILY BHLH TRANSCRIPTION FACTOR 4	
CHROMOSOME 12; 12q24.1	385
1.47. ASIC1 - ACID SENSING ION CHANNEL SUBUNIT 1 CHROMOSOME 12;	
12q13.12	385
1.48. ATF1 - ACTIVATING TRANSCRIPTION FACTOR 1 CHROMOSOME	
12;12q13.12	386
1.49. ATF7 - ACTIVATING TRANSCRIPTION FACTOR 7 CHROMOSOME	
12;12q13.13	386
1.50. ATF7IP - ACTIVATING TRANSCRIPTION FACTOR 7- INTERACTING	
PROTEIN CHROMOSOME 12;12p13.1	386
1.51. BCL7A - B-CELL CLL/LYMPHOMA 7A CHROMOSOME 12;12q24.31	386
1.52. BRAP - BRCA1-ASSOCIATED PROTEIN CHROMOSOME 12;12q24.12	386
1.53. BTG1 - B-CELL TRANSLOCATION GENE 1 CHROMOSOME 12;12q21.33	387
1.54. CCND2 - CYCLIN D2 CHROMOSOME 12;12p13.32	387
1.55. CD163 - CD163 ANTIGEN CHROMOSOME 12;12p13.31	387
1.56. CD63 - CD63 ANTIGEN CHROMOSOME 12;12q13.2	387
1.57. CD9 - CD9 ANTIGEN CHROMOSOME 12;12q13.31	387
1.58. CDK2 - CYCLIN-DEPENDENT KINASE 2 CHROMOSOME 12;12q13.2	388
1.59. CDK2AP1 - CDK2-ASSOCIATED PROTEIN 1 CHROMOSOME 12;12q24.31	388
1.60. CDK4 - CYCLIN-DEPENDENT KINASE 4 CHROMOSOME 12;12q14.1	388
1.61. CDKN1B - CYCLIN-DEPENDENT KINASE INHIBITOR 1B CHROMOSOME	
12;12p13.1	388
1.62. CHFR - CHECKPOINT PROTEIN WITH FHA AND RING FINGER DOMAINS	
CHROMOSOME 12;12q24.33	389
1.63. CKAP4 - CYTOSKELETON-ASSOCIATED PROTEIN 4 CHROMOSOME	
12;12q23.3	389
1.64. CRY1 - CRYPTOCHROME 1 CHROMOSOME 12;12q23.3	389
CONCLUSION	389
REFERENCES	390
 SUBJECT INDEX	 5; 7

FOREWORD

The collection of diseases known as cancer has been recognized as a deadly disease for more than 4000 years. Amazing improvements in the treatment of cancer have occurred in the past century. Still, however, understanding the molecular basis of cancers' origins remains incomplete. Neoplasms are complex diseases that involve mutations or aberrant expression of dozens of genes. The pace of cancer genetics research has expanded exponentially following the sequencing of the human genome. While a tremendous boon for cancer researchers, there have been numerous missed opportunities because the overwhelming numbers of papers published make it nearly impossible for any cancer researcher to keep up.

Dr. Satish Ramalingam and colleagues provide this extensive compendium of cancer genes. The catalog summarizes key data which implicates each gene in one or more cancers and summarizes key studies that explore each mechanism of action. The organization, by the chromosomes on which the genes are encoded, allows both experts and neophytes to cross-reference and facilitate their research objective(s).

The monograph is a compendious primer that will be a valuable resource for cancer biologists, clinical oncologists and students engaging in basic discovery, translational research, or clinical treatment of cancer.

Danny R. Welch, PhD
University of Kansas Cancer Center
Kansas City, Kansas, USA

PREFACE

Cancer incidence is rising and has become a leading cause of death in many cities worldwide. It is well documented that cancer initiation and progression depend on the genes expressed in the cell's genome. It is imperative to understand the genetics of this dreaded disease to win the war against it. As we attempted to understand the latest update about all cancer-related genes in all the chromosomes, we noticed a clear lacuna because no books cover all the important genes that play a role in cancer presented chromosome-wise for easy understanding. We have decided to fill the gap and compiled most of the genes that are identified to play an important role in cancer. We delve into the world of cancer-causing genes and their location on each chromosome. This book will provide valuable mechanistic insights about the mutations and dysregulation of cancer genes that provide an advantage for cancer cell survival during each stage of tumorigenesis. This volume provides a comprehensive overview of the cancer-causing genes located on chromosomes 1-12 and serves as an invaluable resource for researchers, medical professionals, and anyone interested in the genetic basis of cancer.

Satish Ramalingam

Department of Genetic Engineering, School of Bioengineering
SRM Institute of Science and Technology
Kattankulathur-603203
India

List of Contributors

Abhishek Mitra	Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India 603203
Aishwarya Raja	Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India 603203
Anindita Menon	Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India 603203
Harini Hariharan	Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India 603203
Muthu Vijai Bharath Vairamani	Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India 603203
Ravi Gor	Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India 603203
Satish Ramalingam	Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India 603203
Saurav Panicker	Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India 603203
Sayooj Madhusoodanan	Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India 603203
Shivani Singh	Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India 603203
Sivasankari Ramadurai	Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India 603203
Thilaga Thirugnanam	Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India 603203
Yamini Chandrapraksh	Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India 603203

CHAPTER 1

Chromosome 1**Ravi Gor¹, Saurav Panicker¹ and Satish Ramalingam^{1,*}**¹ *Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India*

Abstract: Chromosome 1 is the largest human chromosome, constituting approximately 249 million base pairs. Chromosome 1 is the largest metacentric chromosome, with “p” and “q” arms of the chromosome almost similar in length. Chromosome 1 abnormalities or inclusion of any mutations leads to developmental defects, mental, psychological, cancer, *etc.*, among the most common diseases. 1/10th of the genes in chromosome 1 have been reported its involvement in cancer growth and development. These cancer genes result from chromosomal rearrangement, fusion genes, somatic mutations, point mutation, gene insertion, gene deletion, and many more. Some of these cancer-causing genes appear to be involved in cancer more often, and other novel genes are also enlisted in this chapter.

Keywords: Cancer, Developmental defects, Fusion gene, Gene, Gene insertion, Gene deletion, Metacentric, Mutation, p-arm, Point mutation, Psychological, q-arm, Somatic mutation.

1. INTRODUCTION

Chromosomes are the large chunk of hereditary material that carries information from four nucleotides. This together makes a list of instructions for making proteins, regulatory elements, and other nucleotides required to maintain the growth and normal development of the cells. A human cell constitutes 22 pairs of autosomes and two sex chromosomes, one from each parent. Chromosome 1 is the largest human chromosome, with about 249 million long DNA base pairs, representing about 8% of the total DNA in cells. Chromosome 1 likely contains 2000 to 2100 genes that function cooperatively to achieve the existence of a well-functioning cell. Since we know there are approximately more than 2000 genes coded in chromosome 1 alone, we take a deep look into how many are reported to be involved in cancer disease. The Atlas of Cancer Genetics and Cytogenetics in Oncology and Haematology is a freely available database where all the inform-

* **Corresponding author Satish Ramalingam:** Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India; E-mail: rsatish76@gmail.com

ation about the genes involved or has been reported for the cancer disease is updated regularly.

The list involves the proteins, microRNA, long non-coding RNA, *etc.*, which are now included in the list. Among the 2000 genes on chromosome 1, 1/10th of its dynamic cancer growth and development have been reported. Out of these many genes, we have listed here some t, some top-notch genes that are repeatedly coming into the limelight and showing involvement in cancer.

1.1. MUC1: Mucin-1 Chromosome 1; 1q22

MUC1 protein is widely studied, and its expression is increased in various cancer types like breast, pancreatic, colon, *etc.* Human MUC1 protein is translated as a long single polypeptide, which auto cleaves into two subunits resulting in the formation of a non-covalent heterodimer. The MUC1-N subunit is expressed at the cell surface by forming a complex with the MUC1-C cytoplasmic subunit located in the cytoplasm [1]. Under typical situations, this assembly helps define polarity and create a protective mucous barrier in specialized organs, gastrointestinal and respiratory tracts, or lumen lining ducts. In a different scenario of stress conditions, the cell's polarity is lost, and the MUC1 protein is now positioned everywhere. MUC1-C cytoplasm domain is a 72 amino acid-long polypeptide and consists of various motifs which play an essential role in signaling. One of the binding motifs is CQC which is necessary to form a MUC1-C oligomer. The oligomerization process is critical for transporting MUC1-C to the nucleus and further its interaction with importin β , which helps transport MUC1-C to the nucleus. Inside the nucleus, MUC1-C associates with p53, β -catenin/TCF4, estrogen receptor α [ER α], NF- κ B p65, and STATs. In MUC1-C, phosphorylation of the YEKV site induces the binding of β -catenin to the SAGNGGSSLS sequence. This stabilizes the β -catenin and activates Wnt target genes, such as *cyclin D1* and CTFG. The cytoplasm subunit MUC1-C interacts with receptor tyrosine kinases [*e.g.*, ErbB1- 4] and participates in downstream signaling pathways activating EGFR, FGFR3, PDGFR β , and Met [2, 3]. MUC1-C tail domain also starts EZH2 and BMI1 in triple-negative breast cancer epigenetic reprogramming. MUC1-C interacts with MYC and selectively activates the MTA1 and MBD3 genes. These are components of NuRD signaling. This results in the activation of the NuRD complex and drives dedifferentiation and reprogramming of triple Negative Breast Cancer Cells [4].

1.2. NTRK1: Neurotrophic receptor Tyrosine Kinase-1 Location: Chromosome 1; 1q23.3

NTRK1 encodes a Tropomyosin receptor kinase [Trk]; these tyrosine kinases are membrane-bound and activated by neurotrophins. Some neutrophils which

activate the receptors are Brain-derived neurotrophic factor [BDNF], nerve growth factor [NGF], neurotrophin-3, and neurotrophin-4. Neurotrophin signaling results in cell proliferation, survival, the fate of the neural precursor's cell, programmed cell death, *etc* [5]. As the Trk receptors are activated by the neurotrophins, their function independent of the neurotrophins is also reported, which makes them an oncogene. The fusion of the tropomyosin gene with the locus of the extracellular locus of the Trk gene leads to the constitutive expression of the Trk gene, which results in continuous cellular proliferation [6]. Higher expression of the neurotrophins is a clear indication of the progression of cancer and decreases the survival of the patients [7].

1.3. PBX1: Pre-B-Cell Leukemia Transcription Factor-1 Chromosome 1; 1q23.3

PBX1 (Fig. 1) encodes a protein involved as a transcription factor and belongs to the PBX homeobox family. A fusion protein E2A-PBX1 is produced by the translocation of the t(1;19) (q23.3;p13). This chimeric protein contains transcriptional activation domains from E2A and the homeodomain of PBX1. This complex will disrupt the transcriptional regulation of genes under PBX1 control [8]. Fusion protein E2A-PBX1 has been reportedly associated with pre-B-Cell acute lymphoblastic leukemia. Overexpression of the chimeric protein E2A-PBX1 positive cells in mice has shown hyper-phosphorylation of PLC γ 2, which is essential in the proliferation. Its binding has been located to understand the mechanism behind the E2A-PBX1 for enhancing the proliferation using bioinformatics analysis. It has been found that the chimeric protein binds to the kinases located upstream of the PLC γ 2 gene, that is, ZAP70, LCK, and SYK. Expression of these kinases helps in the phosphorylation of the PLC γ 2 and further its involvement in the proliferation [9]. The E2A-PBX1 fusion protein is also detected in non-small cell lung cancer, shows a standard genetic change, and can be used as a biomarker for the early detection of the disease [10].

1.4. ABL2: Tyrosine Protein Kinase ABL2 Chromosome 1; 1q25.2

ABL2 is a tyrosine-protein kinase that activates the cell's survival, invasion, angiogenesis and growth. ABL2 shows overlapping functions with its family member ABL1. A consistent increase in the expression of ABL2 has been reported in advanced high-grade renal, colorectal, and pancreatic tumors. This shows the direct involvement of the ABL2 in the tumor progression [11 - 13]. Reduced expression of ABL2 in non-small cell lung cancer lines reduced cell growth [14]. In the case of other solid tumors like invasive breast carcinoma, lung squamous cell carcinoma, *etc.*, ABL2 showed higher amplification and higher

Chromosome 2

Thilaga Thirugnanam¹, Saurav Panicker¹ and Satish Ramalingam^{1,*}

¹ Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India

Abstract: The human chromosome 2 was formed by a head-to-head fusion mutation caused by two chromosomes of our ancestors. The gorilla and chimpanzee contain 48 chromosomes in contrast to 46 chromosomes in humans. Ten million years ago, the two chromosomes of apes underwent telomere-to-telomere fusion that gave rise to human chromosome 2. Apart from the exciting history, the human chromosome 2 is involved in various genetic conditions caused due to chromosomal deletions and duplications, leading to SATB2 (Special AT-rich sequence-binding protein 2)-associated syndrome, MBD5 (Methyl-CpG-binding domain 5)-associated neurodevelopmental disorder, 2q37 deletion syndrome, partial trisomy 2, myelodysplastic syndrome as well as cancer. These mutations cause different human abnormalities, such as craniofacial anomalies, cleft palate, genitourinary tract anomalies, microcephaly, hypotonia, heart defects, anemia, and myeloid malignancies. This chapter discusses 50 genes of human chromosome 2 involved in various cancer types.

Keywords: Cancer, CFLAR, Leukemia, Metastasis, MYCN, RALB, RAS, REL, RHOB, Tumor.

1.1. APOB - APOLIPOPROTEIN B CHROMOSOME 2; 2p24.1

APOB encoding apolipoprotein B is a glycoprotein involved in composing and distributing lipids, and mutations in this gene translate a shortened protein causing hypocholesterolemia and familial hypobetalipoproteinemia [1]. APOB is involved in liver cancer in which the gene is mutated [2]. APOB was inactivated in hepatocellular carcinoma, which correlated to poor prognosis [2]. APOB gene signature was associated with other verified signature genes in hepatocellular carcinoma samples showing that silencing of APOB was related to poor prognosis in hepatocellular carcinoma [2]. Network analysis results showed that the activity

* Corresponding author Satish Ramalingam: Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India; E-mail: rsatish76@gmail.com

of low-APOB was linked to increased certain regulators necessary for metastasis and oncogenesis and decreased tumor suppressors compared to high-APOB activity in the progression of hepatocellular carcinoma [2].

1.2. BOLL - BOULE HOMOLOG, RNA BINDING PROTEIN CHROMOSOME 2; 2q33.1

BOLL gene (Fig. 1) comes under DAZ or Deleted in Azoospermia gene family is the parent gene and plays a role in spermatogenesis [3]. BOLL was involved in colorectal cancer, where the expression of this gene was upregulated [3]. BOLL promoter was more methylated in colorectal cancer tissues than in normal tissues [3]. Also, BOLL was highly expressed in colorectal cancer cell lines, which led to the proliferation and migration of these cancer cells and increased the number of cells in the S-phase of the cell cycle [3]. These observations indicated that BOLL has an oncogenic property with increased promoter methylation, particularly in colorectal cancer [3]. BOLL could be a potential prognostic cancer for colorectal cancer [3].

1.3. BUB1 - BUB1 MITOTIC CHECKPOINT SERINE/THREONINE KINASE CHROMOSOME 2; 2q13

BUB1 is a serine/threonine kinase that plays a role in cell cycle checkpoint in mitosis. It localizes along with other proteins involved in the spindle checkpoint to the kinetochore during chromosome congression [4]. Upregulation of BUB1 led to augmentation of phosphorylation of SMAD2 protein and cell proliferation in liver cancer tissues compared to normal liver tissues suggesting that BUB1 might have the diagnostic potential of liver cancer [5]. The role of BUB1 in glioblastoma was also reported, where it was overexpressed and led to cell proliferation and tumor development *in vivo* and *in vitro* [6]. It also serves as a poor prognostic factor due to its increased expression in patients with glioblastoma [6].

1.4. CCL20 - C-C MOTIF CHEMOKINE LIGAND 20 CHROMOSOME 2; 2q36.3

CCL20 is involved in various types of cancers. The expression of CCL20 was induced by interleukin-1 β , which activated signaling pathways in non-small cell lung cancer, where it was upregulated compared to normal samples of lung cells. This resulted in the proliferation and migration of lung cancer cells [7]. CCL20 can serve as a therapeutic target for non-small cell lung cancer [7]. CCL20 was highly expressed in breast cancer patients, which led to reduced survival of these patients [8]. Expression of CCL20 also led to bone metastasis in breast cancer, where it increased the activity of nuclear factors, such as kappa-B and

osteoprotegerin in osteoblastic cells and breast cancer cells and suggest that CCL20 has therapeutic potential in breast cancer bone metastasis [8].

1.5. CFLAR - CASP8 AND FADD-LIKE APOPTOSIS REGULATOR CHROMOSOME 2; 2q33.1

CFLAR, an anti-apoptotic protein homologous to caspase-8 commonly known as c-FLIP or Cellular FLICE-like Inhibitory Protein, plays a major role in inhibiting tumor necrosis factor- α (TNF- α) and TNF-related apoptotic factors and apoptosis during chemotherapy [9]. CFLAR, or c-FLIP, was upregulated in various cancers such as cervical cancer, hepatocellular cancers, head and neck squamous cell carcinoma, and colorectal cancers [9]. c-FLIP also plays a role in non-Hodgkin lymphomas (NHLs), where the expression of c-FLIP could assist in finding the progression of tumors and prognosis of NHLs [10]. c-FLIP inhibits the ligands of death receptors during chemotherapy, causing resistance in cancer cells [10].

1.6. CREB1 - CAMP RESPONSIVE ELEMENT BINDING PROTEIN 1 CHROMOSOME 2; 2q33.3

CREB1 is a transcription factor that controls the proliferation of cells by phosphorylation and dephosphorylation [11], which is targeted by miRNAs in different cancers, such as colorectal, breast, gastric, and ovarian cancer serving as a potential target to treat cancer [12]. miR-122 was one of the miRNAs that targeted CREB1 in bladder cancer in which CREB1 was overexpressed in bladder cancer cell lines and tissues, and miR-122 regulated the expression of *CREB1*, leading to cell invasion and cell proliferation which further could serve as a potential target for bladder cancer [11]. *CREB1*, along with miR-373, was induced by norepinephrine led to colon cancer cell's invasion, proliferation, and metastasis [13].

1.7. CTLA4 - CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 CHROMOSOME 2; 2q33.2

CTLA-4 (Fig. 1) is a glycoprotein that plays a significant role in the immune response. It is expressed on the membranes of T cells to inhibit T cell division and is also involved in the cell cycle and cytokinesis [14]. Expression of CTLA-4 with single nucleotide polymorphisms (SNPs) was observed in various cancers such as melanoma, hepatocellular carcinoma, colorectal cancer, cervical cancer, renal cell carcinoma, etc [14]. An SNP in exon 1 of CTLA-4 leads to a threonine-to-alanine (A/G) exchange [15]. When this SNP in breast cancer was compared to normal breast, the incidence of the GG genotype was reduced in patients with breast cancer. Also, the AA genotype was correlated to the tumor size, indicating that CTLA-4 polymorphism promotes tumor formation [15].

Chromosome 3

Saurav Panicker¹ and Satish Ramalingam^{1,*}

¹ Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India

Abstract: Myriad genes in the genome have been implicated in cancer. However, a focused compilation of genes from the same chromosome would provide a valuable detailed yet succinct catalog for researchers, advantageous in quickly understanding the leading roles played by these genes in cancer. This chapter fulfills the above aim of furnishing a pocket dictionary- like a concise yet meticulous explanation of many genes from Chromosome 3, describing these genes' functional essentialities in various cancers. Such a judicious collection of genes from a single chromosome is probably the first of its kind. The multiple inputs in this chapter from Chromosome 3 include oncogenes (BCL6, RAF1), tumor suppressor genes (SRGAP3, FHIT), transcription factors (FOXP1, MITF), fusion genes (MECOM), and many other types. With approximately 1085 genes spanning 198 million base pairs, Chromosome 3 constitutes 6.5% of the total DNA.

Keywords: Ductal carcinoma, Glioma, Leukemia, Melanoma, MicroRNA, Neuroblastoma, Oncogene, Oncoprotein, Prostate cancer, Stem cells, Tumorigenesis.

1. INTRODUCTION

Chromosome 3 consists of 198 million base pairs. Hence, chromosome 3 roughly symbolizes 6.5% of the total deoxyribonucleic acid in 1 cell. Chromosome 3 is a metacentric chromosome closely associated with many congenital disabilities including deafness. Let us take a deeper look at some of the genes from Chromosome 3 that have been reported in cancer.

1.1. BCL6: B-Cell Lymphoma 6 Chromosome 3; 3q27.3

After BCL6 discovery in B-cell lymphomas, BCL-6 was widely regarded as an oncogene [1]. The BCL-6 locus undergoes translocations in diffuse large B-cell

* Corresponding author Satish Ramalingam: Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India; E-mail: rsatish76@gmail.com

lymphomas [DLBCL] [1]. Such translocations cause the promoter switch of the BCL-6 coding region [1]. BCL6 can initiate tumorigenesis through the suppression of DNA damage checkpoints [1]. BCL6 has been under current scrutiny to consider it a prospective drug target [1]. BCL6 has been reported in solid and hematological cancers [1]. BCL6 gene expression is essential for NSCLC cell survival [1].

1.2. RAF1: Rapidly Accelerated Fibrosarcoma, Chromosome 3; 3p25.2

RAF1 codes for c-RAF (Fig. 1). RAF1 impacts cellular migratory potentials, cell cycle, apoptosis, and senescence [2]. In the RASRAF- MEK-MAPK cellular signaling pathways, RAF1 has a significant effect [2]. RAF1 can be used as a prognostic marker in NSCLC patient's post-therapy [2]. RAF functions as a cellular oncogene. Even metastasis and invasive potential can be determined from the oncogenic hits in RAF [including RAF1] [2, 3].

1.3. TFG: Tropomyosin-Receptor Kinase Fused Gene Chromosome 3; 3q12.2

TFG fusion proteins have been described to cause tumorigenesis [4]. The function of this TFG protein in cancer has had paradoxical reports; some reports state that TFG could function as a tumor suppressor, while others say that TFG could serve as an oncoprotein [4]. TFG has been implicated in metastatic melanoma with a tumor suppressor function [5]. TFG has been identified as a mutational hotspot that could hold clinical significance for diagnosing and treating metastatic melanoma [5].

1.4. SRGAP3: SLIT-ROBO Rho GTPase-Activating Protein 3 Chromosome 3; 3p25.3

SRGAP3 gene (Fig. 1) codes for an enzyme that regulates actin and microtubule dynamics [6]. SRGAP3 is a negative modulator of Rac1 [6]. SRGAP3 functions as a tumor suppressor in mammary epithelial cells [6]. SRGAP3 expression is depleted in breast cancer cells [6]. SRGAP3 under expression would promote anchorage-independent growth of breast cancer cells [6]. Lower levels of SRGAP3 expression have been reported in osteosarcomas and invasive breast carcinomas [7].

1.5. GATA2: GATA Binding Protein 2 Chromosome 3; 3q21.3

GATA2 is a crucial endothelial transcription factor that regulates Androgen Receptor [AR] activity [8]. GATA2 has been linked with the progression of prostate cancer in an AR-dependent and independent manner [8]. GATA2 hyper-expression in prostate cancer rapidly augments proliferation, drug resistance, and

metastatic invasion [8]. GATA2 is a prominent factor for the marked aggressiveness in prostate cancer and, henceforth, could be a suitable target for novel drug therapies [8].

Chromosome 3




Fig. (1). This figure displays the loci of the genes from Chromosome 3 whose roles in cancer have been explained in this chapter. Sayooj Madhusoodanan designs this diagram.

Chromosome 4

Anindita Menon¹, Ravi Gor¹, Saurav Panicker¹ and Satish Ramalingam^{1,*}

¹ Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India

Abstract: Chromosome 4 represents around 6 percent of the total DNA in the cell with 191 million DNA base pairs. Genetic changes in chromosome 4, such as somatic mutation, and chromosomal rearrangement like translocation, gene deletion, *etc.*, have been reported to develop several types of cancer. This includes leukemias, multiple myeloma, oesophageal squamous cell carcinoma, prostate cancer, breast cancer, bladder cancer, *etc.* In this chapter, we have listed genes residing in chromosome 4, which further frequently support cancer development, progression, and metastasis.

Keywords: Bladder cancer, Breast cancer, Cancer, Gene deletion, Leukemia, Metastasis, Multiple myeloma, Oesophageal squamous cell carcinoma, Prostate cancer, Somatic mutation, Translocation.

1.1. AAA2 - AORTIC ANEURYSM, FAMILIAL ABDOMINAL 2 CHROMOSOME 4; 4q31

AAA2 is associated with an abdominal aortic aneurysm. ATPase family AAA domain-containing protein 2 (ATAD2) is related to many cellular processes, such as cell proliferation, invasion, and migration. Knocking of this gene in HeLa and SiHa cells showed a reduction in the capacity for invasion and migration and inhibited growth and clonogenic potential in these cell lines [1]. This gene is also a therapeutic target in various tumors, and profiling reveals dysregulation of ATAD2 specifically in Oesophageal Squamous Cell Carcinoma (ESCC). In-vivo experiments showed the suppressive effect of siRNA-mediated ATAD2 silencing on tumor growth in nude mice. Thus, downregulating the gene restrains the malignant phenotype of ESCC through inhibition of the Hedgehog signaling pathway [2].

* Corresponding author Satish Ramalingam: Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India; E-mail: rsatish76@gmail.com

1.2. ABCG2- ATP BINDING CASSETTE SUBFAMILY G MEMBER DOMAIN 29 CHROMOSOME 4; 4q34.1

They are a member of the ADAM family and are membrane-anchored proteins that structurally are similar to snake venom disintegrins with implicated biological processes involving cell-cell and cell-matrix interaction, including fertilization, muscle development, and neurogenesis. This protein encodes a gene highly expressed in the testis and is involved in spermatogenesis—alternate splicing results in multiple transcript variants. ADAM29 has been a susceptible locus with risk factors in breast cancer under genome-wide significance. Transcript expression was found more in breast cancer tissue than in normal tissue. They may be a prognostic marker for human breast cancer and a novel therapeutic target [3].

1.3. AFF1- AF4/FMR2 FAMILY MEMBER 1 CHROMOSOME 4; 4Q21.3-q22.1

This gene (Fig. 1) encodes a member of the AF4/ lymphoid nuclear protein related to the Fragile X syndrome family of proteins, which have been implicated in human childhood lymphoblastic leukemia, fragile X chromosome, intellectual disability, and ataxia. Members of this family have three conserved domains N- the terminal homology domain, the AF4/ lymphoid nuclear protein domain, and a C- terminal homology domain. The protein regulates RNA polymerase II-mediated transcription through elongation and chromatin remodeling functions. The translocation of genes results in fusion genes. These fusion genes may be due to genetic and environmental factors [4].

1.4. AFP-ALPHA-FETOPROTEIN CHROMOSOME 4; 4q13.3

AFP is a type of plasma protein produced in the yolk sac and the liver during fetal life. AFP expression in adults is associated with hepatocarcinoma and teratoma and has prognostic value for managing advanced gastric cancer. However, hereditary persistence of alpha-fetoprotein is also found, but these individuals show no obvious pathology. The protein is thought to be the fetal counterpart of serum albumin. The AFP and albumin genes are both present in tandem in the same transcriptional orientation on chromosome 4. AFP is found in monomeric, dimeric, and trimeric forms. They also bind to copper, nickel, fatty acids, and bilirubin. The level of AFP in amniotic fluid can be used to measure renal loss of protein to screen spina bifida and anencephaly, which are disorders that are caused due to improper development of neural tubes. DNA methylation of its promoter is the driving mechanism of such overexpression(>400ng/ml). These

tumors show a distinct phenotype characteristic, such as poor differentiation, enrichment of progenitor features and enhanced proliferation [5]. AFP concentration in blood serum is the most specific tumor marker for screening and diagnostic methods [6].

Chromosome 4




Fig. (1). This figure displays the loci of the genes from Chromosome 4 whose roles in cancer have been explained in this chapter. Sayooj Madhusoodanan designs this diagram.

Chromosome 5

Sayooj Madhusoodanan¹, Saurav Panicker¹ and Satish Ramalingam^{1,*}

¹ Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India

Abstract: Chromosome 5 presents an extensive collection of genes, and includes several cancer-associated ones. The contribution of chromosome 5 in abnormalities is evident through somatic translocations, germline, somatic, and, in some instances, expression of genes. Various syndromes are associated with chromosome 5, such as 5q minus syndrome, leading to the development of acute myeloid leukemia, PDGFRB-associated chronic eosinophilic leukemia contributing to acute myeloid leukemia, and myelodysplastic syndromes. Studies propose that a few genes on chromosome 5 play important roles withinside the increase and department of cells. When chromosome segments are deleted, as in a few instances of AML and MDS, those crucial genes are missing. Without those genes, cells can develop and divide too speedy and in an out-o-control way. Researchers are trying to perceive the genes on chromosome five that might be associated with AML and MDS.

Keywords: Cellular differentiation, Epigenesis, Follicular variants, Hypermethylation, Intercellular communication, Microsatellite instability, Multi-drug resistance, Polymorphism, Signet-ring cancer, Signal transduction, Translocation.

1.1. AACSP1: ACETOACETYL-COA SYNTHETASE PSUEDOGENE 1. CHROMOSOME 5; 5q35.3

AACSP1 is a pseudogene and is reported to regulate genes similarly to LncRNAs in the human genome. In renal cell carcinoma, alterations in this gene are observed, and this was because LncRNAs and pseudogenes are closely related to survival and recurrence, suggesting they can serve as potential prognostic markers and are worth further investigation [1]. AACSP1 is involved in lipid metabolism and serves as a marker for it. In a study on non-small cell lung carcinoma, it was observed that there is a direct correlation between the changes in the concentrations of lipid metabolites with changes in the expression levels of AACSP [2]. In

* Corresponding author Satish Ramalingam: Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India; E-mail: rsatish76@gmail.com

asbestos-related lung cancer, DNA methylation changes were observed in the DNA methylation regions (DMR) in T and N between the asbestos-exposed and non-exposed cases, and AACSP1 showed lowered asbestos-related hypomethylation in lung tumors with asbestos-exposed cases [3].

1.2. ABLIM3: ACTIN BINDING LIM PROTEIN FAMILY MEMBER 3. CHROMOSOME 5; 5q32

ABLIM3 is the third member of the actin-binding LIM protein subgroup. ABLIM3 expression is highest in the heart, lungs, liver (fetal and adult), brain/cerebellum, CNS, and spinal cord. The expression profile of the abLIM3 gene supports a suggested role in hepatoma development [4]. The knockdown of ABLIM3 resulted in significant impairment of hepatitis C virus replication in HCV-induced hepatocellular carcinoma [5]. The expression of ABLIM3 mRNA is downregulated for triple-negative breast cancer and adjacent non-tumor tissues [6]. Hyper or hypomethylation of ABLIM3 is observed in connection with thyroid cancer. The mutation of ABLIM3 in Kidney renal clear cell carcinoma may play a key role in kidney cancers. The signal transduction and system processes were enriched and interacted between different cancers, reflecting the standard processes in tumor progression and development [7].

1.3. ACOT12: ACYL-COA THIOESTERASE 12. CHROMOSOME 5; 5q14.1

Acyl-CoA thioesterase 12 (ACOT12) is the major enzyme known to hydrolyze acetyl-CoA's thioester bond in the liver cytosol [8]. In a study, it was observed that there is a close association between increased acetyl-CoA levels and hepatocellular carcinoma (HCC) metastasis. Down-regulation of ACOT12 is correlated with metastasis and poor prognosis of HCC. ACOT12 functionally suppresses HCC metastasis. ACOT12 regulates acetyl-CoA metabolism, and histone acetylation down-regulation of ACOT12 promotes HCC metastasis by epigenetic induction of TWIST2 [9]. ACOT12 is linked with growth and invasion potential.

1.4. ACSL6: ACYL-COA SYNTHETASE LONG-CHAIN FAMILY 6. CHROMOSOME 5; 5q31.1

The ACSL6 gene (Fig. 1), called acyl CoA synthetase 2 (*ACS2*) and fatty acid CoA long chain 6, encodes a long-chain acyl-CoA synthetase. This enzyme is essential in lipid metabolism and cell ATP generation pathways [10]. A study suggests that t(5;12) (q23-31; p13)/ETV6-ACSL6 gene fusion in chronic

leukemia renders cancer cells resistant to treatment using a tyrosine kinase inhibitor [11]. Another study suggests that the expression of ACSL6 was down-regulated and serves as a potential tumor suppressor gene in leukemia. In addition, ACSL6 was decreased in most forms of cancers, except colorectal cancer [12].

ACSL6 is highly expressed in brain tissue. A bioinformatics study in colorectal cancer found that ACSL6 is upregulated compared to healthy tissue. ACSL6 is speculated to support the accumulation of lipid droplets in fatty liver disease, thereby required for the early stages of hepatocellular carcinoma development [13].

1.5. ACTBL2: ACTIN BETA LIKE 2 [HOMO AAPIENS (HUMAN)]. CHROMOSOME 5; 5q11.2

Actin beta-like 2 (ACTBL2) was found to have higher levels in colorectal tumor samples, indicating ACTBL2 association and differential upregulation in colorectal cancer, thereby potentially serving a function in developing markers for colorectal cancer [14]. A study found that increased expression of ACTBL2 was observed in human pancreatic ductal adenocarcinoma [15]. In a survey of human breast cancer cell lines, ACTBL2 was one of the top ten genes to be upregulated [16]. ACTBL2 is a cytoskeletal protein abundantly expressed in vascular smooth muscle cells. ACTBL2 was most strongly associated with epithelial ovarian cancer risk [17]. ACTBL2 is found to differentiate between conventional and follicular variants of papillary thyroid cancer [18].

1.6. ACTBP2: ACTB PSEUDOGENE 2 [HOMO SAPIENS (HUMAN)]. CHROMOSOME 5; 5q14.1

The ACTBP2 locus (Fig. 1) consisting of AAAG repeats on human chromosome 5 is one of the most polymorphic short tandem repeat systems [19]. ACTBP2 is used as a marker in studying microsatellite instability in cancer cells [20]. In a study on ovarian cancer, the microsatellite instability at the ACTBP2 locus is found in 20% of the cancers [21]. ACTBP2 can be used as a microsatellite repeat marker to assess patients with bladder cancer using a non-invasive technique and thereby can be used as a potential biomarker for bladder cancer patients [22]. Knowing the sensitivity of ACTBP2 in bladder tumors, it was used to detect non-small cell lung cancers (NSCLC), detecting an alteration in primary lung tumors. Hence, markers sensitive to NSCLC may also be used for detecting tumors from other organs [23]. A study detected loss of heterozygosity at the ACTBP2 locus in the plasma of small-cell lung cancer patients [24]. ACTBP2 shows a high rate of

Chromosome 6

Shivani Singh¹, Saurav Panicker¹ and Satish Ramalingam^{1,*}

¹ Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India

Abstract: Chromosome 6 is among the 23 pairs of chromosomes in humans and it spans about 170 million base pairs. Several cancer genes have been identified to have a role in cancer development. Cancer is also a genetic disease caused due to changes in the genes that control cell function, such as cell division and cell growth. Most of these cancer genes either act as tumor suppressors or possess an oncogenic potential. Oncogenes like ROS1, MYB, HMGA1, *etc.*, induce tumorigenesis by playing a role in DNA repair, replication, transcriptional regulation, and mRNA splicing. When these genes are highly expressed, they result in the transformation of normal cells to malignant cells; on the other side, tumor suppressor genes like IGF2R, AIM1, IRF4, *etc.*, reduce tumorigenicity and invasive potential. Thus, reduced expression of these genes due to loss of heterozygosity, deletion or any epigenetic modifications can induce tumor formation. Also, some genes can either suppress or induce tumor formation given the cellular location and condition, such as CCN2, TNF, *etc.* Along with these, different types of structural abnormalities can be observed on chromosome 6, such as chromosomal translocation, deletion, duplication, and inversion. These abnormalities on both p and q arms have been known to contribute to the growth and spread of cancer by impacting the expression of cancer genes. Aberrant expression of the genes can also be influenced by fusions, missense mutations, non-missense mutations, silent mutations, frame-shift deletions, and insertion at the molecular level. Some genes can maintain stem-cell-like properties by regulating the expression of cell surface markers like Oct4, Nanog, Sox4, *etc.* This chapter explains important cancer genes, genetic mutations, and gene variations that can influence the risk of having cancer and induces cancer formation.

Keywords: A Cancer stem cell, Chromosome 6, Chromosomal translocation, Deletion, Oncogenes, Tumor suppressor genes.

* Corresponding author Satish Ramalingam: Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India; E-mail: rsatish76@gmail.com

1.1. GENE- *AFDN*; AF-6; AFADIN, ADHERENS JUNCTION FORMATION FACTOR LOCATION: 6p27

AFDN gene (Fig. 1) encodes a multi-domain protein that plays a key role in the organization of epithelial structures of the embryonic ectoderm and is also involved in the signaling and organization of cell junctions during embryogenesis. Aberrant expression of the *AFDN* gene has been shown to induce epithelial-to-mesenchymal [EMT] transition leading to cell migration, invasion, and proliferation in cancer, such as breast cancer, colon cancer, and pancreatic cancer.

Low expression of *AFDN* has been associated with many types of tumors, such as osteosarcoma, breast cancer, and gastric cancer.

1.1.1. The Disease of Relevance

- *AFDN* gene is involved in chromosomal translocation [6, 11][q27;q23] in the case of acute myeloid leukemia [AML] by forming a fusion partner with the acute lymphoblastic leukemia [*ALL-1*] gene. This self-association of the protein afadin activates the oncogenic potential of the MLL-afadin fusion protein. Maintaining the expression on *MLL-AFDN* [*AF6*] driven oncogenic gene expression requires the continuous activity of the histone-methyltransferase DOT1L [1, 2].
- In breast cancer, phosphorylation of afadin by the Akt signaling pathway at Ser1718 promotes the relocalization of afadin from the adherens junction to the nucleus, which further results in breast epithelial cell migration. This relocalization can also occur due to the presence of wild-type or Ser1718Asp mutant afadin that is nuclear restricted and also enhances cell migration. Increased metastatic relapse in breast carcinoma is associated with afadin low expression [3, 4].
- Silencing of *AFDN* expression is known to reactivate the ERK signaling pathway, and this interaction promotes the metastasis phenotype in osteosarcoma cells by stably expressing claudin-2 [*CLDN2*]. Reduced expression of *CLDN2* and *AFDN* are found to participate in pulmonary metastasis of OS and thus can be used as a potential molecular marker for the diagnosis of OS and can also help to determine the prognosis [5].
- Downregulation of long non-coding RNA [lncRNA] *MLLT4-AS1* is significantly associated with lymph node metastasis, distant metastasis, and a shorter disease-free interval in Gastric Cancer. Thus in this cancer, it acts as a tumor suppresser gene, and down-regulation of *MLLT4-AS1* is a potential marker of a poor prognosis. Few studies have shown that infection with *H.pylori* can reduce the expression of afadin, leading to cell migration [6, 7].
- In colon cancer, *AFDN* or afadin physically interacts with Cystic fibrosis

transmembrane conductance regulator [*CFTR*] at a cell to cell contacts, so knockdown of *CFTR* results in reduced stability of afadin protein and enhanced malignancies [8].

- Reduced expression of *AFDN* induces transcription of Snail, which is an EMT inducer, thus promoting *tumorigenesis* in human pancreatic adenocarcinoma [9].
- Loss of *AFDN* expression results in myometrial invasion and high histological grade in patients with `uterine corpus endometrial carcinoma. It is known to induce chemoresistance to cisplatin and so can be used as a marker of chemoresistance to cisplatin [10].

1.2. GENE- DEK; DEK PROTO-ONCOGENE LOCATION: 6p22.3

DEK gene (Fig. 1) codes for nuclear protein, and its expression has been linked to numerous cancer occurring through multiple mechanisms. It is involved in DNA repair, replication, transcriptional regulation, and mRNA splicing, so any changes in the gene expression can lead to tumorigenesis. *DEK* overexpression has been reported in several malignancies like leukemia, melanoma, hepatocellular carcinoma, malignant brain tumors, uterine cervical cancer, lung cancer, glioblastoma, urinary bladder cancer, ovarian cancer, and most sarcoma cell carcinoma. The resequence project of the cancer genome has shown a heterozygous missense mutation [K348N] of *DEK* in the case of renal tumors.




Fig. (1). This figure displays the loci of the genes from Chromosome 6 whose roles in cancer have been explained in this chapter. Sayooj Madhusoodanan designed this diagram.

Chromosome 7

Muthu Vijai Bharath Vairamani¹, Harini Hariharan¹ and Satish Ramalingam^{1,*}

¹ Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India

Abstract: Chromosome 7 consists of 159 million base pairs, and around 950 genes, representing at least 5 percent of the entire DNA in a cell. Various genes that regulate cell division and cellular growth are present in Chromosome 7. Aberrations in these genes can therefore lead to tumorigenesis. Lymphomas and Leukemia have been frequently correlated with abnormalities on chromosome 7. Aberrations in chromosome 7, such as aneusomy in prostate cancer, gene amplifications in gastric cancer, and chromosomal gain in glioblastoma, are some of the starkly real ramifications of genetic abnormalities on chromosome 7. Numerous essential genes from Chromosome 7, including ABCB5, BRAF, CDK6, EGFR, ETV1, EZH2, IL6, and TWIST1, involved in cancer have been explained in this chapter.

Keywords: Liver cancer, Breast cancer, Colorectal cancer, Esophageal cancer, Gastric cancer, Leukemia, Lymphoma, Melanoma, Ovarian cancer, Pancreatic cancer, Prostate cancer, Renal cancer.

1.1. ABCB5 - ATP BINDING CASSETTE SUBFAMILY B MEMBER 5 LOCATION: CHROMOSOME 7; 7p21.1

This gene encodes for a member of the ATP-binding cassette [ABC] transporter superfamily of integral membrane proteins. These proteins participate in ATP-dependent transmembrane transport of structurally diverse molecules, ranging from small ions, sugars, and peptides to more complex organic molecules [1]. This ABCB5 protein is said to promote the invasiveness and metastasis of cancer cells in both breast and colorectal cancer [2, 3]. This protein has also been proven to regulate a Pro-Inflammatory Cytokine Signalling Circuit and thereby maintain melanoma-initiating cells [4].

* Corresponding author **Satish Ramalingam**: Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India; E-mail: rsatish76@gmail.com

1.2. ACTB – ACTIN BETA LOCATION: CHROMOSOME 7; 7p22.1

This gene encodes one of six different actin proteins. Actins are highly conserved proteins involved in cell motility, structure, integrity, and intercellular signaling [5]. The ACTB protein has been used as a reference gene to measure the expression levels of many tumors. Abnormal expression of ACTB has also been reported in liver, melanoma, renal, colorectal, gastric, pancreatic, esophageal, lung, breast, prostate, ovarian cancers, leukemia and lymphoma. These abnormal levels of ACTB are said to improve the invasiveness of tumors and help in cancer metastasis [6 - 8].

1.3. AGR2 - ANTERIOR GRADIENT 2 LOCATION: CHROMOSOME 7; 7p21.1

This gene encodes a member of the disulfide isomerase [PDI] family of endoplasmic reticulum [ER] proteins that catalyze protein folding and thiol-disulfide interchange reactions. This protein plays a role in cell migration, cellular transformation, and metastasis and is a p53 inhibitor [9]. As a p53 inhibitor, ARG2 has been implicated in many cancers, including breast and non-small lung cancer, as a metastasis promoter [10 - 12].

1.4. AKAP9 - A-KINASE ANCHORING PROTEIN 9 LOCATION: CHROMOSOME 7; 7q21.2

The A-kinase anchor proteins [AKAPs] are a group of structurally diverse proteins with the everyday function of binding to the regulatory subunit of protein kinase A [PKA] and confining the holoenzyme to discrete locations within the cell. This gene encodes a member of the AKAP family [13]. AKAP9 proteins have been implicated in thyroid, colorectal, gastric, and breast cancer [14]. The gene resulting from the fusion of AKAP9 and BRAF has been said to activate thyroid cancer by manipulating the MAPK pathway [15].

1.5. AMPH – AMPHIPHYSIN LOCATION: CHROMOSOME 7; 7p14.1

This gene encodes a protein associated with the cytoplasmic surface of synaptic vesicles [16]. AMPH is also a critical protein for breast cancer progression [17]. It is also said to manipulate the Ras-Raf-MEK-ERK signal pathway and originally acted as a tumor suppressor for non-small cell lung cancer. Still, mutations in the gene can help activate cancer [18].

1.6. AQP1 - AQUAPORIN 1 LOCATION: CHROMOSOME 7; 7p14.3

This gene encodes a small integral membrane protein with six bilayer-spanning domains that function as a water channel protein. This protein permits passive

water transport along an osmotic gradient [19]. AQP1 is said to be overexpressed in both lung cancers and a particular subgroup of basal-like breast cancers [20, 21]. It was also observed that when AQP1 was knocked down in human ovarian cancer cells, it inhibited their growth and invasiveness [22].

1.7. BRAF - B-RAF PROTO-ONCOGENE, SERINE/THREONINE KINASE LOCATION: CHROMOSOME 7; 7q34

This gene encodes a protein belonging to the RAF family of serine/threonine protein kinases. This protein regulates the MAP kinase/ERK signaling pathway, which affects cell division, differentiation, and secretion [23]. The BRAF protein regulates the Ras-Raf-MEK-ERK signal pathway. Therefore, mutations in this gene lead to the progression of multiple cancer types [24]. Multiple cancer progression resulting from the fusion of AKAP9 and BRAF has been said to activate thyroid cancer by manipulating the MAPK pathway [15, 25].

1.8. CARD11 - CASPASE RECRUITMENT DOMAIN FAMILY MEMBER 11 LOCATION: CHROMOSOME 7; 7p22.2

The protein encoded by this gene (Fig. 1) belongs to the membrane-associated guanylate kinase [MAGUK] family, a class of proteins that functions as molecular scaffolds for the assembly of multiprotein complexes at specialized regions of the plasma membrane [26]. Mutations in the CARD11 gene are responsible for the progression of Cutaneous Squamous Cell Carcinoma [27]. CARD11 has also been associated with Human Diffuse Large B Cell Lymphoma [28].

1.9. CCM2 - CCM2 SCAFFOLD PROTEIN LOCATION: CHROMOSOME 7; 7p13

This gene (Fig. 1) encodes a scaffold protein that functions in the stress-activated p38 Mitogen-activated protein kinase [MAPK] signaling cascade. The protein interacts with SMAD-specific E3 ubiquitin-protein ligase 1 [also known as SMUR-F1] *via* a phosphotyrosine binding domain to promote RhoA degradation.

The protein is required for endothelial cell's normal cytoskeletal structure, cell-cell interactions, and lumen formation [29]. CCM2 has been implicated in the tumorigenesis of many cancers.

It is also hypothesized that the CCM2 protein can be a biomarker for various cancers [30].

Chromosome 8

Muthu Vijai Bharat Vairamani¹, Harini Hariharan¹ and Satish Ramalingam^{1,*}

¹ Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India

Abstract: Chromosome 8 spans more than 146 million DNA base pairs, and represents between 4.5 and 5 percent of the total DNA in cells. Sixteen percent of these genes and their mutations have been identified to play a role in cancer development. Cancer is a genetic disease at the somatic cell level. Multiple gene mutations usually precede them throughout one's life. Oncogenes such as Myc, Lyn, Atad2, *etc.*, from chromosome 8 promoted cancer cell proliferation, invasion, and migration. The increased expression of these proteins can transform a normal cell into a cancer cell. Chromosome 8 also houses multiple tumor suppressor genes, such as Dlc1, E2f5, Gata4, Ido1, *etc.* These proteins, when expressed, reduce the chances of tumor initiation within cells. Thus, mutations leading to the reduced expression of these genes are associated with multiple cancers. Mutation of other functional genes like Ank1, Ctsb, Ext1, Il7, *etc.*, has also been implicated in various cancers for their role in increasing the invasive nature of cancers by regulating angiogenesis and facilitating cancer metastasis. Cancers can also stem from the translocational mutations of genes in chromosome 8. This chapter explains essential cancer genes, genetic mutations, and gene variations that can cause an increased risk of cancer and its progression.

Keywords: A Cancer stem cell, Chromosome 6, Deletion, Gene Mutations, Oncogenes, Tumor suppressor genes.

1.1. ADAM28: ADAM METALLOPEPTIDASE DOMAIN 28 CHROMOSOME 8; 8p21.2

This gene encodes a member of the ADAM (a disintegrin and metalloprotease domain) family. Members of this family are membrane-anchored proteins structurally related to snake venom disintegrins and have been implicated in various biological processes involving cell-cell and cell-matrix interactions, including fertilization, muscle development, and neurogenesis [1]. ADAM28 is

* Corresponding author Satish Ramalingam: Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India; E-mail: rsatish76@gmail.com

overexpressed in non-small cell lung carcinomas and has also been proven to correlate with cancer cell proliferation and lymph node metastasis [2].

ADAM28 has also been associated with the proliferation of human breast carcinoma cells through the cleavage of insulin-like growth factor binding protein-3 [3].

1.2. ADAM32: ADAM METALLOPEPTIDASE DOMAIN 32 CHROMOSOME 8; 8p11.22

This gene encodes a member of the disintegrin family of membrane-anchored proteins that play a role in diverse biological processes, such as brain development, fertilization, tumor development, and inflammation. This gene is predominantly expressed in the testis. The encoded protein undergoes proteolytic processing to generate a mature polypeptide comprised of a metalloprotease, disintegrin, and epidermal growth factor-like domains [4]. ADAM32 has been suspected of having a role in multiple carcinomas for its ectodomain-shedding activity of several proteins like Tumour necrosis factor (TNF)- α [5]. GNMTF predictions have also shown that ADAM32 can act as a driver gene for cancer cell proliferation [6].

1.3. ADAM7: ADAM METALLOPEPTIDASE DOMAIN 7 CHROMOSOME 8; 8p21.2

This gene encodes a member of the ADAMs family of zinc proteases. These transmembrane proteins play roles in multiple processes, including cell signaling, adhesion, and migration. The encoded protein lacks protease activity and may play roles in protein-protein interactions and cell adhesion processes, including sperm-egg fusion [7]. Mutations in the ADAM7 gene have been associated with the development of melanomas [8]. It has also been identified as one of 7 biomarker genes in high-risk prostate cancer [9].

1.4. ADAM9: ADAM METALLOPEPTIDASE DOMAIN 9 CHROMOSOME 8; 8p11.22

This gene encodes a member of the ADAM [a disintegrin and metalloprotease domain] family. Members of this family are membrane-anchored proteins structurally related to snake venom disintegrins and have been implicated in various biological processes involving cell-cell and cell-matrix interactions, including fertilization, muscle development, and neurogenesis [10]. Elevated

ADAM9 expression has been detected during the transition of human LNCaP prostate cancer cells from an androgen-dependent to an androgen-independent and metastatic state [11] and *In vivo* targeting of ADAM9 gene expression using lentivirus-delivered shRNA has been shown to suppress prostate cancer growth [12]. ADAM9 has also been shown to be highly expressed in pancreatic cancer [13], human breast cancer [14], and renal cell cancer [15].

1.5. ADGRB1: ADHESION G PROTEIN-COUPLED RECEPTOR B1 CHROMOSOME 8; 8q24.3

ADGRB1, also known as BAI1 (Brain-specific Angiogenesis Inhibitor), contains at least one 'functional' p53-binding site within an intron, and its expression is induced by wildtype p53. There are two other brain-specific angiogenesis inhibitor genes, designated BAI2 and BAI3, which, along with BAI1, have similar tissue specificities and structures; however, only BAI1 is transcriptionally regulated by p53. BAI1 is postulated to be a member of the secretin receptor family, an inhibitor of angiogenesis, and a growth suppressor of glioblastomas [16]. ADGRB1 prevents the formation of Medulloblastomas by protecting p53 from mdm2-mediated degradation [17]. It has also been implicated to have in hepatocellular carcinoma [18]

1.6. ADHFE1: ALCOHOL DEHYDROGENASE IRON CONTAINING 1 CHROMOSOME 8; 8q13.1

The ADHFE1 gene encodes hydroxy acid-oxoacid transhydrogenase [EC 1.1.99.24], which is responsible for the oxidation of 4-hydroxybutyrate in mammalian tissues [19]. ADHFE1 is a breast cancer oncogene and promotes orthotopic tumor growth [20]. It has also been found that the hyper-methylation of the ADHFE1 gene can cause colorectal cancer [21 - 23].

1.7. AGO2: ARGONAUTE RISC CATALYTIC COMPONENT 2 CHROMOSOME 8; 8q24.3

This gene encodes a member of the Argonaute family of proteins which play a role in RNA interference. The encoded protein is fundamental and contains aAZ and PIWI domains. It may interact with dicer1 and play a role in short-interfering-RNA-mediated gene silencing. Multiple transcript variants encoding different isoforms have been found for this gene [24]. The AGO2 gene has a high incidence of gene alterations across cancer types, including invasive breast carcinoma [23.30%], colon and rectum adenocarcinoma [12.3%], bladder

Chromosome 9

Thilaga Thirugnanam¹, Yamini Chandrapraksh^{1,#}, Sivasankari Ramadurai^{1,#}, Abhishek Mitra^{1,#}, Ravi Gor¹, Saurav Panicker¹ and Satish Ramalingam^{1,*}

¹ Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India

Abstract: Chromosome 9 represents approximately 4.5 percent of the total DNA in cells, and it's a submetacentric type of chromosome. Chromosomal abnormalities in chromosome 9 have been reported in different kinds of cancer, for example, deletion of the long-q arm, a fusion of ABL1 with BCR results in the ABL1-BCR fusion gene, *etc.* Bladder cancer, chronic myeloid leukemia, *etc.*, are several cancer types resulting from genetic changes in the genes present in chromosome 9. Dysregulation of the tumor suppressor genes or activation of the oncogene from chromosome 9 has supported the normal cell's transformation. Here, we have listed a few top genes reappearing themselves as causative agent for cancer development in cancer and types of cancer.

Keywords: ABL1-BCR, Bladder Cancer, Chromosomal Abnormalities, Chronic Myeloid Leukemia, Fusion Gene, Genetic Change, Oncogene, q-arm, Submetacentric, Tumor Suppressor.

1.1. ABCA1 - ATP-BINDING CASSETTE, SUBFAMILY A, MEMBER 1 CHROMOSOME 9; 9q31.1

ABCA1 belongs to the ATP-binding cassette transporter (ABC) superfamily [1]. It is involved in the reverse transport of the cholesterol pathway, which helps translocate the phospholipids and cholesterol from the cytoplasm to the cell surface embedded with apolipoproteins and monitors the pathway [1]. Several mutations in this gene lead to a high-density lipoprotein deficiency disorder called Tangier disease, which further causes atherosclerosis [1]. Disruptions in *ABCA1* expression cause cancer and tumor progression [2]. A study observed the correlation between ABCA1 and cholesterol in colorectal cancer where the upregulation of ABCA1 resulted in cell invasion, cell proliferation, and Epithe-

* Corresponding author **Satish Ramalingam**: Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India; E-mail: rsatish76@gmail.com

Equal authorship and equal contribution status.

lial-Mesenchymal transition away from the primary location [2]. In addition, ABCA1 might induce metastasis and growth of tumors [2]. *ABCA1* gene expression might be a potential biomarker for the prognosis of colorectal cancer [2].

1.2. ANXA1 - ANNEXIN A1 CHROMOSOME 9; 9q21.13

ANXA1 belongs to the superfamily of annexin proteins which binds to phospholipids on cell membranes involving physiological functions such as cellular differentiation, membrane trafficking, proliferation, and signal transduction [3]. In addition, expression of ANXA1 is reported in various cancers, including bladder, liver, lung, skin, prostate, pancreatic, colorectal, endometrial, esophageal, melanoma, cervical cancer, and oral cancer [4]. In prostate cancer, ANXA1 was downregulated under hypoxic conditions resulting in cell invasion and metastasis of the prostate cancer cell line, indicating that ANXA1 might be a useful therapeutic marker for prostate cancer undergoing metastasis [5]. In colorectal cancer, the expression of ANXA1 was increased, leading to early metastasis of lymph nodes and invasion, suggesting that ANXA1 could serve as a biomarker for colorectal cancer prognosis [4].

1.3. AQP3 - AQUAPORIN 3 CHROMOSOME 9; 9p13.3

AQP3 is a water channel protein belonging to the aquaporin protein family that regulates the influx and efflux of water in cells [6]. This protein is expressed in the membrane of chorions in the amniotic fluid and placenta in humans to maintain amniotic fluid homeostasis [6]. Apart from water homeostasis, AQP3 also regulates the flow of solutes of neutral charges, such as urea and glycerol [6]. AQP3 is expressed in normal tissues like the brain, lungs, pancreas, prostate, epithelial cells, breast, liver, ovary, and bladder [7]. Moreover, the expression of AQP3 is increased in pancreatic, colon, hepatocellular carcinoma, and lung cancer [7]. This protein induces proliferation, migration, and invasion of cancer cells, and promotes epithelial-mesenchymal transition [7].

1.4. BAG1 - BCL2- ASSOCIATED ANTHANOGENE 1 CHROMOSOME 9; 9p13.3

BCL2- associated anthanogene 1 (*BAG1*) is widely involved in the development, progression, and metastasis of cancer; overexpression of BCL2- associated anthanogene 1 (*BAG1*) is reported in breast cancer, it consists of the development of lesions, tumor development, cancer progression, and metastasis [8].

1.5. BRINP1 - BONE MORPHOGENETIC PROTEIN/RETINOIC ACID-INDUCIBLE NEURAL-SPECIFIC PROTEIN 1 CHROMOSOME 9; 9q33.1

This gene is commonly known as Deleted in Bladder Cancer Chromosome 1 (*DBCCI*), which is widely seen in patients with Bladder and Lung cancer, and the effect of this gene is seen lesser in the early stages of lung cancer; this gene is further silenced so that proliferation, migration, invasion of the cancer cells can be controlled, and Lung cancer can be reduced and prevented. Downregulation of Deleted in Bladder Cancer Chromosome 1 (*DBCCI*) is done by DNA methylation [9].

1.6. CA9 - CARBONIC ANHYDRASE 9 CHROMOSOME 9; 9p13.3

Acid transport is significant in cancer cell progression, transport metabolons, cancer invasion, and cell migration; an acid vehicle is seen between bicarbonate and Carbonic anhydrase (*CA9*), which alters the pH, acid, and bases level, which leads to the progression of cancer [10].

1.7. CCL19 - C-C MOTIF CHEMOKINE LIGAND 19 CHROMOSOME 9; 9p13.3

CCL19 is associated with cervical cancer and is also involved in epithelial to mesenchymal transition cervical cancer. The overexpression of the C-C motif ligand 19 (*CCL19*) leads to the progression of cervical cancer and is also abnormally expressed, which involves tumor development [11].

1.8. CCL21 - C-C MOTIF CHEMOKINE LIGAND 21 CHROMOSOME 9; 9p13.3

CCL21 is expressed during the formation of lymphoid organs and vessels, interacting with glycosaminoglycans and embedding the proteins on endothelial cell surfaces [12]. The CCL21 induces breast cancer proliferation, and this ligand is responsible for the metastasis and progression of tumors in the breast cells and tissues [12].

1.9. CD274 - MOLECULE PROGRAMMED CELL DEATH 1 LIGAND 1 CHROMOSOME 9; 9p24.1

CD274 is also known as PD-1 or Programmed death 1, which regulates the suppression of the immune response to Th1 cytotoxicity *via* negative feedback [12]. This protein is also involved in various cancer, such as Hodgkin's

Chromosome 10

Saurav Panicker¹ and Satish Ramalingam^{1,*}

¹ Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India

Abstract: Chromosome 10 contains various genes that are significantly involved in tumorigenesis. These genes described herein that play roles in cancer comprise receptor tyrosine kinases (FGFR2), proto-oncogenes (FRAT1, RET), tumor suppressor genes (PTEN, KLF6), and also genes involved in signal transduction (MAPK8), gene fusions (CCDC6, KIF5B, VTI1A), developmental processes (GATA3, NODAL), Epithelial-Mesenchymal transition (ZEB1, VIM) and epigenetic regulation (MLLT10). This chapter provides a compilation of many such genes from Chromosome 10 that are associated with cancer, with vivid delineations of the underlying molecular mechanisms of each gene in its contribution to cancer initiation, progression and metastasis. Genes that are insufficiently investigated but implicated in tumorigenesis have also been described in this chapter.

Keywords: Apoptosis, Cell Cycle, Cytogenetic Location, Deletion, Down-regulation, Gene, Gene Amplification, Invasion, Malignant, Migration, Mutation, Signal Transduction, Translocation, Tumor Progression, Upregulation.

1.1. ALL1 – ACUTE LYMPHOCYTIC LEUKEMIA LOCATION: CHROMOSOME 10; 10q21

ALL1 protein has been reported in Leukemia. ALL1 gene undergoes translocation with chromosomal band 11q23 [1]. Mutations in this gene have been reported in 5- 10% of Acute Leukemia [1]. ALL gene fusion with chromosome 11 has been reported in 11% of adult *de novo* AML [Acute myeloid leukemia] [2]. ALL1 gene mutation and Trisomy 11 have been frequently correlated in multiple adult AML patients. ALL1 gene undergoes partial tandem duplication of an internal position of itself, thereby triggering leukemogenesis [2]. Various types of self-fusions and tandem duplications among exons of ALL genes have been observed in AML [3]. Such self-fusions and tandem duplication among the exons of the ALL1 gene contribute to genetic instability leading to leukemia [2, 3].

* Corresponding author Satish Ramalingam: Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India; E-mail: rsatish76@gmail.com

1.2. ALOX5 - ARACHIDONATE 5-LIPOXYGENASE LOCATION: CHROMOSOME 10; 10q11.21

ALOX5 gene (Fig. 1) is off 71.9-kilo base pairs. The gene consists of 14 exons and 13 introns. The ALOX5 protein is of 673 amino acids and has a molecular weight of 78 kilo-dalton. Cells involved in inflammatory responses and allergy express ALOX5 [4]. Such cells include neutrophils, basophils, mast cells, and eosinophils [4]. ALOX5 gene dysregulation has been reported in Chronic Myeloid Leukemia [CML] [5]. ALOX5 is a critical regulator of Cancer Stem Cells [CSC] in CML [5]. ALOX5 promotes the activity of Leukemia Stem Cells in CML [5]. ALOX5 deficiency failed BCR-ABL to induce leukemogenesis in CML [5]. Neutrophils support lung metastasis of breast cancer *via* ALOX5-dependent leukotriene release [4]. Inhibition of ALOX5 using Zileuton inhibited breast cancer's lung metastasis and the activity of Leukemia Stem Cells in CML [4, 5]. Contrary to the theory that ALOX5 is a novel target against CSC, it was further reported that deletion of ALOX5 in the tumor microenvironment could aggravate lung cancer progression [6] since ALOX5 gene products had antitumor roles in the tumor microenvironment *via* T-cell recruitment [6]. Hence, recent research suggests that caution must be taken while targeting ALOX5 though it provides a novel target against CSC [5, 6].

1.3. CAMK1D- CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE ID` LOCATION: CHROMOSOME 10; 10p13

CAMK1D belongs to the CaMK family of Ca²⁺/calmodulin-regulated serine/threonine protein kinases [7]. CAMK1D gene is amplified and overexpressed in most breast cancers [7]. CAMK1D overexpression in non-tumorigenic breast epithelial cells indicated EMT [Epithelial Mesenchymal Transition]. CAMK1D is reported to be the driver oncogene in multiple basal-like tumors. CAMK1D is identified to be a novel oncogene that promotes EMT in breast cancer and could be used as a potential therapeutic target for basal-like tumors [7]. CAMK1D is essential for cellular proliferation [7 - 9]. CAMK1D has been shown to promote fibroblast proliferation by activating the cyclin D-1/CDK4 complex [7, 8]. It's yet to be found if CAMK1D enhances proliferation through the exact mechanism in other cell types. Nevertheless, CAMK1D is associated with CREB pathway activation in basal breast cancers [7]. It's yet to be speculated if CREB protein is a direct target of CAMK1D or if CAMK1D associates with genes containing CREB sequence [7, 8, 10]. Such an example is the CCND1 gene that codes for Cyclin D-1 and contains a CREB sequence in its promoter region [7, 10]. CAMK1D is a new potential target for molecular-targeted therapy since CAMK1D promotes

EMT, which is vital to invasion and metastasis, adding to the fact that kinases have always been used as previous drug targets [7].

Chromosome 10




Fig. (1). This figure displays the loci of the genes from Chromosome 10 whose roles in cancer have been explained in this chapter. Sayooj Madhusoodanan designed this diagram.

1.4. ARID5B: AT-RICH INTERACTION DOMAIN 5B LOCATION: CHROMOSOME 10; 10q21.2

ARID5B gene mutations have been reported in childhood acute lymphoblastic leukemia [ALL] [11]. ALL is the most common malignancy reported in childhood [12]. Genome-Wide Association Studies [GWAS] have exposed the genetic risk

Chromosome 11

Harini Hariharan¹, Saurav Panicker¹ and Satish Ramalingam^{1,*}

¹ Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India

Abstract: Over the years, many scientists and doctors have been treating the deadly cancer disease but cannot find a permanent treatment for this disease. Also, sometimes it becomes tough to understand the mechanisms and causes of cancer as it is a very complex disease that involves many biological processes. Due to the redundancy in our biological system, cancer progression becomes very easy, thus making it difficult to cure. To find the root cause of this disease, we should know what genetic alterations are causing cancer progress and who is participating in these alterations, like proteins, signaling pathways, or genes. Cancer is caused due to various reasons; it can be due to genetics but primarily due to carcinogens, causing mutations in the genes, thereby making them an oncogene. The Proto-oncogenes are those genes that usually assist the growth of tumor cells. The alteration, mutation, or increased copy number of a particular gene may turn into a proto-oncogene, which could end up completely activated or turned on. Many Tumor-causing alterations or mutations related to oncogenes are usually acquired and not inherited. These tumor-causing mutations often activate oncogenes *via* chromosomal rearrangement or changes in the chromosome, which sequesters one gene after another, thereby permitting the first gene to prompt the alternative. Search which genes are involved in different cancer types would help scientists proceed with new methods for finding a cure for this disease. This article will depict which genes and their location on which chromosomes, specifically on chromosome 11, are related to different types of cancer.

Keywords: Cancer, Chromosome 11, Chromosome Rearrangements, Gene Duplication, Mutation, Oncogene, Proto-oncogene.

1.1. GENE - NUP98; NUCLEOPORIN 98. LOCATION - 11p15.4.

NPCs alter the shipping of macromolecules among the cytoplasm and nucleus and are made up of several polypeptide subunits, many of which belong to the nucleoporin class or family. NPCs belong to the nucleoporin family that codes for 186-

* Corresponding author Satish Ramalingam: Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India; E-mail: rsatish76@gmail.com

kDa precursor-protein that encounters autoprolytic-cleavage to form a 98kDa and 96kDa nucleoporin. The ninety-eight kDa nucleoporin includes a repetition of the Gly-Leu-Phe-Gly (GLGF) domain and indulges in many cellular mechanisms, such as nuclear export, mitotic progression, nuclear import, and activation of gene expression. The 96kDa nucleoporin is more or less a scaffold factor of NPC. Proteolytic cleavage is critical for targeting the proteins to NPC. Translocations among the NPC gene and many companion genes have been located in several leukemias. Rearrangements commonly bring chimeras with the N-terminal GLGF area of this NPC gene to the C terminus of the companion gene. The alternative-splicing consequences in a couple of transcript mutations or variants encoding several isoforms, as a minimum of 2 that are proteolytically-processed. Some variants here lack the area that encodes for the ninety-six kDa nucleoporin. The mammalian genes have been established to amalgamate several genes following chromosome translocations in T-cell acute-lymphocytic leukemia and acute-myelogenous leukemia. The NUP98 gene is among numerous genes placed within the imprinted-gene area of 11p15.5, an important tumor-suppressor gene area. The alterations in this area are usually correlated with adrenocortical carcinoma, Wilms tumor, ovarian tumor, Beck with-Wiedemann syndrome, breast cancer, rhabdomyosarcoma and lung cancer. The study of AML childhood sufferers from Austria diagnosed one NUP98 gene rearrangement in fifty-nine unselected instances. A study intended to identify the NUP98-HOXA9 fusion found that three of two hundred and eight unselected acute-myelogenous cases of leukemia had NUP98-HOXA9 fusion in the Asian group population [1, 2]. Fusion, NUP98-HOXA9 was diagnosed in sufferers with CML-bc (Ph+), and the combined nature of BCR-ABL and NUP98-HOXA9 fusions was established in the experimental mouse model [3, 4].

1.2. GENE - CCND1; CYCLIN D1 LOCATION - 11q13.3

The protein coded through CCND1-gene belongs to the cyclin family, which is notably very conserved. Its contributors are often characterized by elevated protein abundance during the cycle. Cyclins usually function as actuators of CDK kinases. Various cyclins showcase defined patterns of degradation and expressions that contribute to the temporal coordination of every mitotic event. The cyclin D1 configures a complex and actuates as a regulatory or activation subunit of CDK6 or CDK4, whose activation is essential and, indeed, required for the transition phase of the cell cycle (G1/S phase). The protein-CCND1 has been demonstrated to interact with Rb protein, a tumor suppressor. The over-expression, alteration, and mutations of CCND1 involved in the alteration of cell cycle progression are majorly found in several types of cancers, which further contribute to tumorigenesis and oncogenesis. CCND1 actuates as an oncogene

and is frequently over-expressed in many cancers through gene rearrangement or amplification [5 - 7]. The CCND1 alterations inhibiting ubiquitin-mediated degradation, nuclear export, and Thr286 phosphorylation *via* the proteasome have activated the CDK6/4 network, thereby enhancing the malignant transformation and cellular proliferation both *in vivo* and *in vitro* [8 - 10].

1.3. GENE -BIRC3; BACULOVIRAL-IAP REPEAT CONTAINING-3. LOCATION - 11q22.2

BIRC3 gene codes a particular member of the IAP family of proteins that inhibits apoptosis by forming a complex with tumor-necrosis factor receptor-associated elements TRAF2 and TRAF1, possibly *via* interfering with the actuation of ICE-like proteases. The encoded protein hinders apoptosis through the means of serum deprivation; however now no longer affects apoptosis as a consequence of exposure to menadione, a vigorous inducer of free radicals. It incorporates three baculovirus repeats of IAP and a ring-finger domain. Transcript-variants coding the identical isoform had been identified. BIRC3 can potentially enhance the therapeutic resistance in Glioblastoma [11]. GBM survival is enhanced by the functional contribution of BIRC3 *via* its mechanism in hindering the actuation of caspases [12, 13]. Still, it promotes inflammatory techniques *via* the mediation of tumor-necrosis-factor α signaling [14 - 18].

1.4. GENE - POU2AF1; POU-CLASS 2 HOMEBOX-ASSOCIATING FACTOR 1 LOCATION - 11q23.1

The protein is likewise termed as an Oct co-activator from B cells, aka Oct binding complex, and as generally discovered within the literature, BOB1. BOB1 is a transcriptional co-activator expressed basically *via* B-cell lymphocytes and mastery of immunoglobulin and different genes essential for those cell's expressions of CRISP-3, CD20, and CD36 [19]. The regulation of BOB1 has been verified beneficial for figuring out positive lymphomas, such as B-cell lymphomas, as typified in research that uses BAB1 expression to assist perceive lymphomas [19]. The increase in copy number of POU2AF1 was identified in 3 out of 23 patients, informing that the POU2AF1 amplification is not the artifact obtained at the time of establishing a cell line. However, an infrequent POU2AF1 amplification was detected in a small range of cases. However, the frequent amplification of the POU2AF1 gene in MM isn't so low as compared with different gene amplification activities: for instance, the MYCN amplification, one of the essential genetic activities figuring out analysis in neuroblastoma, is thought to be located in much less than 20% on this disease [20].

Chromosome 12

Yamini Chandraprakash¹, Ravi Gor¹, Saurav Panicker¹ and Satish Ramalingam^{1,*}

¹ Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, India

Abstract: Chromosome 12 spans about 134 million DNA building blocks and represents approximately 4.5 percent of the total cellular DNA. Gene dysregulation from chromosome 12 has triggered a cell to transform into a cancerous cell. Different types of genes are present in chromosome 12 that cause colon cancer, ovarian cancer, prostate cancer, ampulla of Vater cancer (Vater cancer), *etc.* These genes play their role in the development and the progression of cancer into metastasis, Epithelial to mesenchymal transition, and overall cancer growth. In this chapter, we have enlisted the genes responsible for cancer and their short introduction.

Keywords: Cancer, Cancerous Cell, Colon Cancer, Cancer Growth, Downregulated, Epithelial-Mesenchymal, Gene Dysregulation, Metastasis, Ovarian Cancer, Prostate Cancer.

1.1. A2M – ALPHA-2-MACROGLOBULIN, CHROMOSOME 12; 12p13.31

The protein encoded by this gene is a protease inhibitor and cytokine transporter. It uses a bait-and-trap mechanism to inhibit a broad spectrum of proteases, including trypsin, thrombin and collagenase. Downregulated DEGs of *A2M* were significantly associated with the “Complement and coagulation cascades” pathway and the “Ras signaling pathway.” Downregulated *A2M* might contribute to the progression of Bladder Cancer [1]. *A2M* out of the seven predicted gene markers was found to encode proteins secreted into urine, providing potential diagnostic evidence for pancreatic cancer [2].

* Corresponding author Satish Ramalingam: Department of Genetic Engineering, SRM Institute of Science and Technology, Kattankulathur, India; E-mail: rsatish76@gmail.com

1.2. A2LM1 - ALPHA 2 MICROGLOBULIN LIKE 1 CHROMOSOME 12; 12p13.31

A2ML1, which are under-expressed in the ER+ group and over-expressed in the ER- group. *A2ML1* which encodes the secreted protease inhibitor α -2-M [A2M]-, like-1 activates mutations in signal transducers of the RAS/mitogen-activated protein kinase [MAPK] pathway [3].

1.3. AACCS-ACETOACETYL-COA SYNTHETASE CHROMOSOME 12; 12q24.31

Acetoacetyl-CoA synthetase [AACCS] is the enzyme responsible for cholesterol and fatty acid synthesis in the cytosol. *AACCS* dysregulation by Sp1 has been reported in neuroblastoma cell lines. *AACCS* gene has been reported in Vater cancer. A small opening connecting the pancreas and bile ducts to the duodenum is called the ampulla of Vater. Mutation in the *AACCS* gene (Fig. 1) causes cancer in this Ampulla of Vater. *AACCS* protein is related to Valine, isoleucine, and leucine degradation pathways. *AACCS* protein is also linked to Ketone body metabolism [4].

1.4. ABCB9 - ATP-BINDING CASSETTE, SUBFAMILY B, MEMBER 9 CHROMOSOME 12; 12q24.31

Paclitaxel is widely used in treating breast cancer; drug resistance increases the failure of chemotherapy. Using microRNA target prediction tools, they have identified that *ABCB9* could be one of the target genes of miR-24. miR-24 can also affect the expression of *ABCB9* to regulate the sensitivity toward paclitaxel of breast cancer cells. It was identified that miR-24 could directly bind to the 3'-UTR of *ABCB9*, thereby inhibiting the translation of *ABCB9* [5].

1.5. ABCC9 - ATP-BINDING CASSETTE, SUBFAMILY C, MEMBER 9 CHROMOSOME 12; 12p12.1

ABC transporters play a major role in prostate cancer [PCa] development, and the *ABC* transporter gene expression was analyzed in PCa and noncancerous prostate tissues [NPT]. *ABCA8*, *ABCB1*, *ABCC6*, *ABCC9*, *ABCC10*, *ABCD2*, *ABCG2*, and *ABCG4* expression of eight *ABC* transporter genes were down-regulated in the absence of the TMPRSS2- ERG fusion transcript Prostate cancer [PCa] as compared to Noncancerous prostate tissue [NPT], and only two genes [*ABCC4* and *ABCG1*] were up-regulated [6].

1.6. ABCD2 - ATP-BINDING CASSETTE, SUBFAMILY 3, MEMBER 2 CHROMOSOME 12; 12q12

X-linked adrenoleukodystrophy [X-ALD] is a peroxisomal disorder which is caused by mutations in the *ABCD1* gene that encodes the peroxisomal ATP-binding cassette [ABC] transporter subfamily D member 1 protein [ABCD1], which is also referred to as the adrenoleukodystrophy protein [ALDP]. Induction of the *ABCD2* gene, which is closest to *ABCD1*, has a possible therapeutic option for the defective ABCD1 protein in X-ALD. X-ALD is caused by mutations that occurred in the *ABCD1* gene, which is also associated with the accumulation of VLCFAs [Very Long Chain Fatty Acids] in the plasma and tissues of the patients. Induction of *ABCD2* can be a better treatment option for X-ALD because expression of this protein can decrease VLCFAs [Very Long Chain Fatty Acids] levels in fibroblasts [7].

1.7. ACRBP - ACROSIN-BINDING PROTEIN CHROMOSOME 12; 12P13-p 12

Myxoid and round cell liposarcoma are formed in soft and fat tissues. Cancer-testis antigens are immunogenic antigens that have an expression restricted to testicular germ cells and malignancies, making them attractive targets for cancer immunotherapy. Gene expression studies reported that expression of various cancer-testis antigens in liposarcoma, with mRNA expression of CTAG1B, CTAG2, MAGEA9, and PRAME, are described in myxoid and round-cell liposarcoma. Overexpression of *NY-ESO-1* in myxoid and round cell liposarcoma, the expression of cancer-testis antigens evaluated are MAGEA1, ACRBP, PRAME, SSX2, and by immunohistochemistry and PRAME, CTAG2, and MAGEA3 by quantitative real-time PCR [8].

1.8. ACSS3 - ACYL-COA SYNTHETASE SHORT CHAIN FAMILY, MEMBER 3 CHROMOSOME 12; 12q21.31

Gastric cancer [GCa] is one of leading cancer in humans. Mitochondrial-derived acetyl-CoA contributing enzymes [acyl-coA synthetase super-family 3; ACSS3] are patient's progression of Gastric Cancer [GCa]. Cholesterol is an essential component for fast-growing cancer cells. The mevalonate pathway is an enzymatic cascade that is responsible for de novo cholesterologenesis. *ACSS3* is a landmark cancer progression gene in Gastric Cancer [GCa] patients, which is part of the biochemical process for the mitochondrial production of acetyl-CoA [9].

SUBJECT INDEX

A

Acid 108, 165, 234, 257, 289, 356
 glutamic 165
 hyaluronic 257, 356
 retinoic 234
 thymidylc 108
 Actin-filament-associated proteins (AFAP) 95
 Activity 36, 45, 115, 116, 194, 207, 244, 259,
 265, 349
 antioxidant 45, 259
 downregulates macrophage 116
 metastatic 36
 motor protein 349
 protease 244
 telomerase 207, 265
 tumor-associated angiogenic 194
 tumor-suppressing 115
 Acute myeloid leukemia (AML) 33, 55, 57,
 90, 160, 162, 249, 251, 253, 307, 324,
 351, 352, 378, 379
 Adipogenesis 115, 125
 AMP-activated kinase 85
 Anchorage-independent growth 53, 79, 170,
 172, 195, 261, 298, 312
 Androgen dependent prostate cancer (ADPC)
 81
 Angiogenesis 36, 42, 43, 45, 95, 97, 166, 168,
 169, 170, 174, 194, 230, 231, 245, 246,
 374
 inhibitor genes 245
 pathologic 374
 tumor-associated 194
 Angiogenic factors 96, 111, 180, 184, 185
 Anti-apoptotic proteins 189
 Anticancer therapy 103, 107
 Apoptosis, cytokine-induced 167
 Apoptotic protease 380
 Atherosclerosis 261, 287

B

Barrett's adenocarcinoma 184
 Beck with-Wiedemann syndrome 345
 Brain tumors 59, 227, 231, 252
 Breast 95, 160, 168, 179, 188, 199, 325
 carcinogenesis 325
 carcinomas 95, 160, 188, 199
 tumorigenesis 168, 179
 Breast cancer 13, 30, 32, 35, 37, 60, 71, 99,
 100, 103, 109, 111, 114, 115, 117, 119,
 120, 123, 160, 166, 173, 174, 193, 196,
 197, 260, 264, 308, 312, 313, 321, 323,
 325, 374, 383, 387
 aggressive 173
 bone metastasis 30
 luminal 312, 321
 metastasis 32, 60, 99, 100, 174, 313, 323
 metastatic 111, 197, 325
 migration 103
 risk 109, 115, 123, 196

C

Cancer(s) 105, 190, 196, 198, 199, 254, 313,
 296, 355, 384
 carcinogen-induced 105
 cell migration 313, 384
 colitis-associated 199
 estrogen-related 198
 nasopharyngeal 254
 neuroendocrine 355
 Hodgkin's lymphoma 190, 196, 296
 risk 190, 196
 Carcinogenic 165, 179, 180
 Carcinomas 8, 16, 33, 43, 63, 119, 166, 172,
 173, 185, 187, 188, 198, 292, 297, 321,
 325, 357, 382
 esophageal squamous cell 8, 16, 63, 119,
 166, 292, 297, 321
 gallbladder 185
 gastric 43, 173, 325, 357, 382

Satish Ramalingam (Ed.)

All rights reserved-© 2023 Bentham Science Publishers

nasopharyngeal 33, 63, 166, 172, 187, 188, 198
 Cervical cancer (CC) 9, 30, 58, 168, 170, 171, 172, 182, 184, 197, 198, 288, 289, 290, 291
 Ciliogenesis 170
 Colon 55, 93, 100, 175, 382
 cancer metastasis 175
 carcinoma 93, 100, 382
 tumors 55
 Colorectal 43, 62, 93, 122, 198, 199, 288, 328
 cancer prognosis 288
 carcinomas 43, 93, 122, 198, 199
 neoplasms 328
 tumorigenesis 62

D

Diabetes 94, 257, 290
 type-2 290
 Disease(s) 6, 77, 92, 95, 97, 115, 230, 265, 290, 331, 348, 353, 359
 autoimmune 77, 230
 cardiovascular 95, 290
 coronary artery 97
 fatty liver 92
 infectious 115
 inflammatory 97
 inflammatory bowel 265, 331
 metabolic 353
 metastatic 348
 prognosis 6
 pylori-related gastric 359
 Disorders 62, 65, 85, 170, 253
 myeloproliferative 85, 170
 neurodegenerative 253
 pituitary hormone 62
 DNA 14, 17, 18, 41, 42, 45, 82, 106, 122, 123, 207, 223, 227, 232, 234, 253, 260, 266, 326, 332, 354, 357, 359, 374, 381
 binding protein(s) 18, 45, 106, 227
 genomic 381
 damage-induced apoptosis 326
 damage responses 357

 demethylases 374
 glycosylase 14
 polymerases 42, 82, 122, 266
 replication 82, 122, 232, 332
 DNA-dependent 82, 128, 266
 ATPase 82
 protein kinase 128, 266
 DNA methylation 44, 72, 91, 178, 199, 289, 374, 381
 regions (DMR) 91
 DNA repair 298, 331
 pathway 298
 process 331

E

Embryogenesis 32, 40, 46, 160, 168, 231, 246, 257, 350, 380
 Endocytosis 17, 188, 228
 clathrin-mediated 228
 Environmental stresses 109
 Enzyme 15, 43, 85, 91, 93, 108, 120, 124, 126, 248, 254, 258, 262, 263, 266, 351, 359, 361, 372, 373, 377, 380, 381
 dihydrofolate reductase 108
 fibrinolytic 266
 fumarase 15
 heme 258
 heterodimeric 266
 metabolic 377
 mRNA editing 380, 381
 nucleotide metabolism 43
 proteolytic 93
 succinate dehydrogenase 124
 telomerase 126
 ubiquitin-conjugating 351
 Epidermal growth factor receptor 195
 Epigenetic-transcriptional activation 347
 Epithelial 7, 12, 14, 84, 107, 115, 160, 161, 168, 194, 195, 206, 208, 234, 248, 292, 311, 328, 377, 378, 380, 385
 mesenchymal transition (EMT) 7, 12, 14, 160, 161, 168, 194, 195, 206, 208, 311, 328, 377, 378, 385

ovarian cancer 7, 84, 107, 115, 234, 248, 292, 380
ERK signaling pathways 170, 185
Erythrocytes 246
Estrogen 206, 255
 activation 206
 induced tumor suppressor 255
ETS proteins 228
Ewing's sarcoma 40

F

Factors 53, 105, 124, 187, 346, 359
 activating signaling 187
 cytokine macrophage migration inhibitory 105
 endothelial transcription 53
 fibroblast growth signaling 124
 growth-inhibitory 359
 tumor-necrosis 346
FAK protein 267
Fatty acid-binding proteins 257
Fibroblast(s) 10, 43, 74, 75, 84, 102, 111, 112, 191, 195, 257, 298, 319, 325, 326, 357, 373, 377, 380
 growth factor (FGF) 43, 84, 111, 112, 195, 257, 319, 325, 326, 377
 somatic 191
 synovial 102
Fibrosarcoma 181
Follicular stimulating hormone (FSH) 79
Fusion protein 3, 163, 170, 177, 184, 328, 350

G

Gastric 34, 36, 58, 63, 79, 84, 94, 121, 160, 166, 174, 198, 203, 223, 261, 318, 320, 373, 375, 376
 cancer 34, 36, 63, 79, 84, 94, 121, 160, 166, 174, 198, 203, 223, 261, 318, 320, 373, 375, 376
 cardia adenocarcinoma 58
Gastrointestinal 80, 81, 124, 202
 stromal tumors 80, 202

tumors 81, 124
Gene(s) 3, 18, 253, 254, 259, 291, 353, 371
 dysregulation 371
 fusion genes 18
 metastasis-promoting 291
 mitochondrial 254
 phosphorylates 259
 transforming 353
 tropomyosin 3
Gliomagenesis 233
Gluconeogenesis 169
Glutathione peroxidase activity 204
GTPase-activating protein 100, 248, 254, 291
GTP 5, 101, 232
 binding proteins 101, 232
 hydrolysis 5

H

Heat shock protein 176, 258, 378
Hematopoiesis 6, 182, 249, 296, 347, 348, 356
Hematopoietic 125, 255
 progenitor cells 125
 progenitors 255
Heparan sulfate biosynthesis 256
Hepatitis 91, 113, 167, 262, 318, 383
 chronic 383
Hepatoblastoma 200
Hepatocarcinogenesis 115
Hepatocarcinoma 72
Hereditary 124, 313, 389
 pheochromocytoma 124
 pituitary tumors 313
 prostate cancer 389
Hormones, gonadotropin-releasing 79
Huntington's disease 228
Hyaluronan 115, 257
 mediated motility receptor 115
 synthase 257
Hypocholesterolemia 28
Hypoglycemia 353

I

Inflammation 41, 75, 78, 93, 97, 102, 118, 230, 244
 chronic 230
Inflammatory 13, 163, 164, 346
 cytokine release 13
 myofibroblastic tumors 163, 164
 techniques 346

L

Leukemia inhibitory factor (LIF) 116, 118
Leukemogenesis 59, 183, 308, 324
Ligase 193, 225, 351
 ubiquitin-protein 193, 225
Liposarcoma 181, 373
Liver cancer 28, 29, 43, 94, 110, 166, 223, 297, 384
Lung carcinomas 174, 385
Luteinizing hormone (LH) 79
Lymph node metastasis 8, 11, 78, 160, 182, 187, 204, 206, 207, 244, 312
Lymphoid neogenesis 77
Lynch syndrome 61

M

Malignancies 9, 55, 120, 122, 161, 162, 163, 169, 172, 175, 178, 180, 190, 259, 265, 349, 357
 hematological 55, 178, 190, 259, 265
 induced 178
 lymphoid 178
 mature B-cell 178
 natural killer-cell 172
Malignant 59, 99, 172
 melanoma 59, 172
 transformation process 99
Metalloproteinases 93
Methionine synthase 120

Migration 12, 17, 29, 39, 40, 41, 71, 77, 78, 84, 93, 102, 169, 187, 195, 203, 243, 244, 288, 348
 endothelial 187
 hypoxia-induced 203
 inhibited 93
 metastatic 195
 nuclear 348
Mitochondrial dysfunction 108
Mitogen-activated protein kinases (MAPK) 5, 9, 15, 124, 167, 188, 193, 225, 314, 315, 372
Mucinous tumors 349
Myelodysplastic syndromes 28, 59, 90, 128, 296
Myelogenous leukemia 117
Myeloid 38, 120, 170, 178, 195
 hyperplasia 170
 leukemia cells 38
 leukemias 120, 178, 195
Myelopoiesis 85
Myoclonus dystonia 361
Myofibroblasts 93

N

Neuroblastoma 5, 32, 38, 39, 52, 60, 124, 181, 191, 202, 314, 346
 tumorigenesis 124
 tumors 32, 314
Nijmegen breakage syndrome 263
Nuclear 81, 186, 229
 respiratory factors (NRF) 81
 ribonucleoproteins 186, 229

O

Oncogenic signaling 185, 327
 pathways 185
 transduction 327
Ovarian 15, 173, 175, 185, 192
 carcinoma 15, 173, 175, 185
 dysfunction 292
Ovarian cancer 12, 63, 380

- apoptosis 380
progression 12
stem cells 63
- P**
- Parkinson's disease 94
Promyelocytic leukemia 207
Prostate cancer 75, 264, 319
 bone metastasis 264
 metastasis 75
 tumorigenesis 319
Protease inhibitor 371
Prostatectomy 8
Proteasome 85, 103, 254, 298, 346, 351
 degradation 351
Protein kinase 9, 11, 41, 42, 123, 167, 188,
 193, 224, 225, 226, 232, 266, 330
 mitogen-activated 9, 167, 188, 193, 225, 330
Proteins 36, 373
 adrenoleukodystrophy 373
 transcriptional repressor 36
Proteolysis 34, 93, 175
 regulated intramembrane 34
Psoriasis 329
- R**
- Renal cancer 35, 56, 61, 119, 174, 223, 247,
 248
Repair, post-DNA replication 14
Retinoic acid receptor responder protein 359
Rheumatoid arthritis 102
Ribonucleotide reductase 43
RNA 17, 29, 45, 186, 229, 315
 binding proteins 45, 229
 helicases 350RNA binding protein 17, 186,
 315
 chromosome 29
- S**
- Saccharomyces cerevisiae* 233
Sarcomas, soft-tissue 193
- Signaling, chemical 127
Silver-Russell syndrome 353
Single nucleotide polymorphisms (SNPs) 5,
 15, 30, 102, 178, 184, 190, 196, 198
Skin 5, 57, 59, 121, 125, 164, 227, 259, 330,
 386
 cancer 5, 59, 121, 125, 164, 227, 259, 330
 lesions 386
 melanocytic tumors 57
Small 3, 10, 29, 38, 81, 82, 121, 122, 232,
 233, 326, 327, 376, 378, 382, 385
 cell lung cancer (SCLC) 3, 10, 29, 38, 81,
 82, 121, 122, 233, 326, 327, 376, 378,
 382, 385
 GTP-binding proteins 232
Somitogenesis 258
Sonic Hedgehog signaling pathway 35
SPARC gene 125
Spermatogenesis 29, 72, 350
SRC proteins 39
Suppressor gene, putative tumor 175
- T**
- Telomere-to-telomere fusion 28
Thyroid 12, 59, 79, 91, 105, 162, 166, 181,
 224, 225, 248, 292, 297
 cancer 12, 59, 91, 105, 166, 181, 224, 225,
 248, 297
 carcinoma 79, 162, 166
 malignancy 166
 morphogenesis 292
TNF-independent pathway 102
Transition, mesenchymal 10, 39, 122, 257,
 260, 289, 371
Transversion mutation 14
Tumor 52, 55, 56, 58, 60, 109, 159, 175, 200,
 202, 204, 295, 298, 387
 carcinogenesis 387
 chemotherapy 109
 cytoplasm 175
 suppressor genes 52, 55, 56, 58, 60, 159,
 200, 202, 204, 295, 298
Tumor cell 184, 328

apoptosis 184
progression 328
Tumour necrosis factor (TNF) 159, 184, 185,
190, 244, 328

V

VEG-F-independent angiogenic gene in
Breast cancer 246
VHL 61, 330
deficiency 330
gene 61
hereditary cancer 61
Vimentin chromosome 329
Virus 5, 178, 318, 383
avian sarcoma 5
cell leukemia 178

W

Wilms' tumor 200